



# **Rubicon Organics Inc.**

**ANNUAL INFORMATION FORM**

**FOR THE YEAR ENDED DECEMBER 31, 2025**

**DATED AS OF MARCH 23, 2026**

## Table of Contents

FORWARD-LOOKING INFORMATION .....	1
CORPORATE STRUCTURE .....	5
GENERAL DEVELOPMENT OF THE BUSINESS .....	6
DESCRIPTION OF THE COMPANY'S BUSINESS.....	8
DIVIDENDS AND DISTRIBUTIONS .....	15
DESCRIPTION OF CAPITAL STRUCTURE .....	15
ESCROWED SECURITIES.....	16
MARKET FOR SECURITIES .....	16
DIRECTORS AND EXECUTIVE OFFICERS.....	16
LEGAL PROCEEDINGS AND REGULATORY ACTIONS .....	19
INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS .....	20
TRANSFER AGENT AND REGISTRAR.....	20
MATERIAL CONTRACTS .....	20
INTERESTS OF EXPERTS.....	20
RISK FACTORS .....	21
ADDITIONAL INFORMATION.....	36

## ANNUAL INFORMATION FORM

In this annual information form (this “AIF”), unless otherwise noted or the context indicates otherwise, the terms “Company,” “Rubicon Organics,” “we,” “our” and “us” refer to Rubicon Organics Inc. and its direct and indirect subsidiaries and the terms “cannabis,” “CBD,” “client,” “license” and “THC” have the meanings given to such terms in the *Cannabis Act* (Canada) (the “Cannabis Act”) and the regulations made under the Cannabis Act (the “Cannabis Regulations”). All financial information in this AIF is prepared in thousands of Canadian dollars, except as otherwise indicated, and is prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board.

### FORWARD-LOOKING INFORMATION

This AIF contains “forward-looking information” and “forward-looking statements” (collectively, “**forward-looking statements**”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions, and beliefs. Such statements can be identified by the use of forward-looking terminology such as “believe”, “expects”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “plan”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Such forward-looking statements are made as of the date of this AIF. Forward-looking statements in this AIF include, but are not limited to, statements with respect to the Company’s:

- expectations regarding its revenue, expenses and operations;
- anticipated cash needs and its needs for additional financing;
- intention to grow the business and its operations;
- expectations with respect to future production, development costs, and capacity;
- expectations with respect to the approval and/or retention of the Company’s licenses and compliance with regulatory requirements;
- expectations with respect to the future growth of the Company’s cannabis products, including delivery mechanisms;
- competitive position and the regulatory environment in which the Company operates;
- expected business objectives for the next 12 months, including optimizing quality and yield, improving product mix to maximize gross margin, and driving cost efficiencies throughout the organization;
- ability to obtain additional funds through the sale of equity or debt commitments;
- ability to attract new customers and retain existing customers;
- ability to attract, hire and retain employees;
- ability to retain organic certification in Canada;
- belief that organic products are expected to command a higher price in the marketplace;
- commentary related to general economic and political conditions;
- ability to obtain new strains;
- medical benefits, viability, safety, efficacy and social acceptance of cannabis;
- anticipated trends and challenges in the industry;
- business and the markets in which it operates;
- anticipated effectiveness regarding approach to risk-mitigation, business continuity planning and supply chain management;
- anticipated success of any future outdoor grow program; and
- the anticipated closing of the transaction for the facility acquisition, and related increased production capacity.

Forward-looking statements contained in certain documents incorporated by reference into this AIF are based on the key assumptions described in such documents. Certain of the forward-looking statements contained herein concerning the cannabis industry and the general expectations of the Company concerning the cannabis industry and concerning the Company are based on estimates prepared by the Company using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the cannabis industry involves risks and uncertainties and is subject to change based on various factors.

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments, and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward-looking statements included in this AIF, the Company has made various material assumptions, including but not limited to (i) obtaining the necessary regulatory approvals; (ii) that regulatory approvals are expected to be maintained; (iii) general business and economic conditions; (iv) the Company's ability to successfully execute its plans and intentions; (v) the availability of financing on reasonable terms; (vi) the Company's ability to attract and retain skilled staff; (vii) market competition; (viii) the products and technology offered by the Company's competitors; and (ix) that the Company's current good relationships with its suppliers, service providers and other third parties are expected to be maintained. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under "*Risk Factors*", which include:

- Risks from potential tariffs and trade regulation changes, which could increase production costs, hinder market expansion, and impact profitability, operational flexibility, and growth prospects;
- the Company faces risks associated with the initial operations from the recently acquired Cascadia Facility, including challenges related to securing licenses, certifications, integration, and production;
- the Company faces risks in international shipments of cannabis products, including legal, regulatory, logistical, and security challenges, which could disrupt deliveries, affect product quality, and result in financial or reputational harm;
- the Challenging Global Financial Conditions due to events such as worldwide political unrest, pandemics, recession, the rising economic impact of tariffs, and high inflationary environment;
- the Company has a limited operating history, a history of losses and the Company cannot assure profitability;
- the Company's ability to continue as a going concern;
- there is no assurance that the Company will maintain profitability or pay dividends;
- there are no assurances the Company's sales channels will remain accessible or that distributors will keep the Company's product listings, which if lost will impact the Company's ability to generate revenue;
- the Company's actual financial position and results of operations may differ materially from the expectations of the Company's management;
- the Company expects to incur significant ongoing costs and obligations relating to its investment in infrastructure, growth, regulatory compliance and operations;
- the Company is reliant on loans secured against the Pacifica and Cascadia Facilities which mature in 2029 and 2030, respectively, and must be repaid by a combination of operating cash flows and refinancing. There can be no certainty that such refinancing will be available at terms acceptable to the Company, or at all;
- the optimization of the Pacifica and Cascadia Facilities is subject to various potential problems and uncertainties; and such optimization may be delayed or adversely affected by a number of factors beyond the Company's control;
- there are factors which may prevent the Company from the realization of growth targets;
- there can be no guarantee that Health Canada or Canada Revenue Agency will extend or renew the licenses or that, if extended or renewed, the licenses will be extended or renewed on the same or similar terms, which could materially and adversely affect the business;
- the Company is subject to changes in laws regulations and guidelines which could adversely affect the Company's future business, financial condition and results of operations;
- a failure to identify the appropriate inputs and estimate the fair value of cannabis plants could result in material adjustments to the Company's results of operations;
- the Company may not be able to develop its products, which could prevent it from ever becoming profitable;

- failure to maintain the organic certification may have an adverse effect on the market price of the Company's products;
- a failure to meet and maintain international regulations and certifications, including European Union Good Manufacturing Practice ("EU-GMP") certification, for the export of cannabis products may impact the results of operations and financial condition of the Company;
- the Company may not be able to maintain its Toronto Stock Venture Exchange ("TSX-V") listing requirements, which could adversely impact the results of the Company's operations or its financial condition;
- the Company may be unable to adequately protect its proprietary and intellectual property rights;
- the Company may be forced to litigate to defend its intellectual property rights, or to defend claims by third parties against the Company relating to intellectual property rights;
- the Company may become subject to litigation, including for possible product liability claims, which may have a material adverse effect on the Company's reputation, business, results from operations and financial condition;
- the Company's operations are subject to environmental regulation in the jurisdictions in which it operates;
- the Company faces competition from other companies that have a higher capitalization and may have more experienced management or may be more mature as a business;
- if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis market;
- the size of the Company's target market is difficult to quantify and investors will be reliant on their own estimates on the accuracy of market data;
- the Company's industry is experiencing rapid growth and consolidation that may cause the Company to lose key relationships and intensify competition;
- the Company may continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions which will dilute the current shareholders;
- the Company currently has insurance coverage; however, because the Company operates within the cannabis industry and due to other issues arising in the insurance market, there are additional difficulties, complexities, and costs associated with maintaining such insurance coverage;
- obtaining new strains and developing new product offerings may not be successful or aligned to consumer demands;
- the cultivation of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others;
- the cultivation of cannabis involves a reliance on third party transportation which could result in supply delays, reliability of delivery and other related risks;
- the Company may be subject to product recalls for product defects self-imposed or imposed by regulators;
- the Company is reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on the Company's finances and operational results;
- the Company has a dependency risk related to business partners and suppliers to satisfy the delivery of products and services;
- the expansion of the medical cannabis industry may require new clinical research into effective medical therapies, when such research is new to Canada and has been restricted in some international jurisdictions;
- under Canadian regulations, a licensed producer of cannabis has restrictions on the type and form of marketing it can undertake which could materially impact sales performance;
- the Company could be liable or face regulatory action for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses to claims against the Company;
- the Company will be reliant on information technology systems and may be subject to damaging cyber-attacks;
- the Company may be subject to breaches of security at its facilities, or in respect of electronic documents and data storage, and may face risks related to breaches of applicable privacy laws;
- the Company's officers and directors may be engaged in a range of business activities resulting in conflicts of interest;
- the Company may further expand our business and operations into jurisdictions outside of Canada, and there are risks associated with doing so;
- changes in the public's perception of medical and/or adult-use cannabis could increase future regulation;
- in certain circumstances, the Company's reputation could be damaged;
- the Company targets, among other segments, the premium adult-use cannabis market, which may not materialize, or in which the Company may not be able to develop or maintain a brand that attracts or retains customers;
- necessary security clearances take time to obtain and may impact the Company's ability to attract and retain board members and officers;
- the Company may not be able to enforce its legal rights;

- the Company has previously sold, and plans to sell, vaping products that may be subject to governmental and private sector actions that aim to reduce or prohibit the sale of these products;
- there is no certainty the Company will be able to achieve its Environmental, Social and Governance (“ESG”) targets;
- the cannabis industry has experienced, and continues to experience, price compression, which may adversely impact the Company’s profitability;
- the adult-use recreational cannabis market in Canada may become oversupplied;
- the Company’s business is subject to risks associated with adverse economic conditions in Canada and globally, including economic slowdown, inflation and the disruption, volatility and tightening of credit and capital markets;
- the cost of compliance and ability to working with unsophisticated individuals and entities may adversely impact the Company;
- regulations and health safety concerns around vaping products may depress or inhibit the sale of certain Company products;
- a failure to adhere to environmental and employee health and safety regulations may give rise to material liabilities;
- failure to develop and maintain an effective system of internal controls increases the risk that the Company may not be able to accurately and reliably report our financial results or prevent fraud, which may harm our business, the trading price of our Common Shares, and market value of other securities;
- due to cannabis affiliations the Company may have difficulty accessing the service of banks and financial institutions, which may make it difficult to operate;
- the Company’s transition to an Enterprise Resource Planning (“ERP”) system entails potential risks such as cost over-runs, resource allocation, temporary decline in productivity, and errors in data migration;
- the Company may be limited on resources and availability of space to increase production volumes at the Pacifica and Cascadia Facilities;
- the Company’s securities have not been registered under the U.S. Securities Act;
- the market price for Common Shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond the Company’s control;
- the Company does not anticipate paying dividends;
- the increase in the number of Common Shares (as defined below) issued and outstanding as a result of public offerings, if any, may have a depressive effect on the price of the Common Shares;
- the ability of a shareholder to recover all or any portion of its investment upon dissolution or termination of the Company will depend on the amount of funds realized and the claims to be satisfied from such funds;
- the continuation of the Company’s business of growing, storing, and distributing medical and recreational cannabis is dependent on the good standing of all licenses required to engage in such activities and upon adhering to all regulatory requirements related to such activities;
- the Company may not be able to obtain or maintain all necessary licenses and permits in a timely manner, which could, among other things, delay or prevent the Company from becoming profitable;
- there is no guarantee on the use of available funds by the Company;
- there can be no assurance that organic products will command a higher price in the marketplace, the results of which could adversely affect the Company’s ability to become profitable;
- failure to meet or maintain the organic certification standards may have an adverse impact on the market price of the Company’s products; and
- the Company’s concentrated ownership structure may hinder shareholder trading due to reduced liquidity and market volatility.

If any of these risks or other unknown risks or uncertainties materialize, or if assumptions underlying the forward-looking statements prove incorrect, actual results might vary materially from those anticipated in those forward-looking statements.

The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not place undue reliance on forward-looking statements contained in this AIF or in any document incorporated by reference. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this AIF are expressly qualified in their entirety by this cautionary statement.


## CORPORATE STRUCTURE

Rubicon Organics was incorporated under the *Business Corporations Act* (British Columbia) (the “**BCBCA**”) on May 15, 2015. On May 22, 2018, the Company changed its name from “West Coast Land Corporation” to “Rubicon Organics Inc.” and replaced its articles in their entirety, the effect of which included adding advance notice provisions for the election of directors. The common shares of the Company (the “**Common Shares**”) are listed on the TSX-V under the symbol “ROMJ” and on the OTCQX under the symbol “ROMJF”.

The address of the Company’s registered and records office is 1200 Waterfront Centre, 200 Burrard Street, PO Box 48600 Vancouver, British Columbia V7X 1T2. The Company’s head office is located at unit 701 – 744 West Hastings Street, Vancouver, British Columbia V6C 1A5. The Company’s corporate website can be accessed at [www.rubiconorganics.com](http://www.rubiconorganics.com).

As of December 31, 2025, Rubicon Organics’ subsidiary details were as follows:

Name	Place of Incorporation	Ownership Percentage
Rubicon Holdings Corp. (“ <b>RHC</b> ”)	BC, Canada	100%



**RHC**, formerly Rubicon Organics Canada Corp., is a wholly-owned subsidiary of the Company, incorporated in British Columbia and licensed under the Cannabis Act as a Licensed Producer (“**LP**”). This licensing enables the Company to cultivate, process, and sell cannabis products across its two complementary British Columbia facilities, the Pacifica Facility, a 125,000 sq. ft. high-tech greenhouse located in Delta, and the Cascadia Facility, a 47,500 sq. ft. state-of-the-art indoor cultivation facility located in Hope, serving both recreational and medical-use markets across Canada and international medical markets.

On January 1, 2024, the Company amalgamated West Coast Marketing Corp. (“**WCMC**”) into RHC. WCMC was a wholly-owned subsidiary of the Company incorporated in British Columbia to hold corporate assets and facilitate operations at the Company’s head office.

On October 1, 2020, the Company amalgamated Bridge View Greenhouses Ltd. (“**Bridge View**”) and Vintages Organic Cannabis Company Inc. (“**Vintages**”) into RHC. As part of this process, the Health Canada license issued under the Cannabis Act and Cannabis Regulations, held by Vintages, was incorporated into the newly amalgamated entity, RHC. Prior to its amalgamation into RHC in 2020, (a) Bridge View, was an indirect wholly-owned subsidiary of the Company incorporated in British Columbia that was purchased in September 2017 and held the Company’s flagship Pacifica Facility assets; and (b) Vintages was an indirect wholly-owned subsidiary of the Company incorporated in British Columbia and was the Licensed Producer for the Company.

## GENERAL DEVELOPMENT OF THE BUSINESS

### Three Year History

#### *Fiscal 2023 (January 1, 2023 to December 31, 2023)*

On January 6, 2023, the Company granted an aggregate of 1,055,000 stock options to certain employees of the Company pursuant to the Equity Plan. The options are exercisable at \$0.90 per share, for a period of 5 years. The options vest over 3 years.

On March 20, 2023, the Company announced the appointment of Michael Detlefsen to its Board effective immediately, and the anticipated nomination of Doris Bitz, Len Boggio, Ian Gordon and Karen Proud (together the "Nominees") to stand for election at the AGM later in 2023. The Nominees must also receive Health Canada's customary security clearance before they can join the Board.

On September 14, 2023, the Company held its Annual General Meeting ("AGM"). At the AGM, the shareholders elected Karen Proud, Len Boggio, Doris Bitz and Ian Gordon to its Board. Doris Bitz was appointed to the Board on October 16, 2023, after being granted security clearance by Health Canada. Len Boggio was appointed as Chair of the Board (the "Chair").

On October 16, 2023, the Company released its third annual Environmental, Social, & Governance Report.

On December 12, 2023, the Company announced that the Company was the winner of KIND Magazine's Cannabis Company of the Year and People's Choice for Best Weed awards.

#### *Fiscal 2024 (January 1, 2024, to December 31, 2024)*

In January 2024, the Company granted an aggregate of 420,000 DSUs pursuant to the DSU plan to independent directors of the Company as compensation for their services in 2023. In addition, the Company granted stock options for a total of 15,000 common shares to an employee.

In February 2024, the Company announced the appointment of Margaret Brodie as Chief Executive Officer and Janis Risbin as Chief Financial Officer. In addition, the Company granted an aggregate of 1,361,106 RSUs to certain executives of the Company.

In March 2024, the Board invited Jesse McConnell, a consultant to the Company, to attend parts of its meetings as an observer.

On July 30, 2024, the Company settled \$25 of director fees with one director of the Company in consideration for the issuance of 59,764 fully paid common shares.

On July 31, 2024, held its Annual General and Special Meeting ("AGSM") where Doris Bitz, Len Boggio, Margaret Brodie, Michael Detlefsen, Ian Gordon, Jesse McConnell, John Pigott, and Karen Proud were elected as directors of the Company for the ensuing year until the next annual meeting of the Company. Jesse McConnell's appointment was subject to being granted security clearance by Health Canada. David Donnan did not stand for re-election.

On July 31, 2024, at the Company's AGSM, the shareholders approved the Company's new Omnibus Equity Incentive Plan. This plan is a fixed plan which provides that the aggregate maximum number of Common Shares that may be issued upon the exercise or settlement of awards granted under the plan is 4,846,192 Common Shares. The Omnibus Equity Incentive Plan replaces the Company's legacy equity incentive plan and legacy DSU plan, and as such, no further grants of stock awards or DSUs can be made under the legacy equity incentive plan or legacy DSU plan.

On July 31, 2024, the Company granted an aggregate of 1,316,233 DSUs to certain independent directors of the Company as compensation for their services in the first half of 2024, and in advance for the following 12 months which vest one year following the date of grant. The Company enlisted a third-party consultant and conducted comprehensive benchmarking to ensure that the compensation aligns with industry standards observed within its peer group.

On September 9, 2024, the Company announced that Jesse McConnell has been appointed to the Company's Board of Directors ("Board") after receipt of security clearance from Health Canada.

On September 9, 2024, the Company awarded a total of 140,459 DSUs under its Omnibus Equity Incentive Plan to a director as compensation for their upcoming service.

In October 2024, the Company announced the publication of its fourth annual Environmental, Social and Governance Report.

On November 27, 2024, the Company announced its extraordinary performance at the 2024 KIND Awards, including Budtender Choice for its super premium brand Simply Bare™ Organic and Brand of the Year with 1964 Supply Co.™

On December 2, 2024, the Company announced it had entered into credit agreements where it has borrowed an aggregate of \$10,000.

On December 23, 2024, the Company announced the promotion of Melanie Ramsey to Chief Operating Officer (“COO”) effective January 1, 2025.

***Fiscal 2025 (January 1, 2025, to December 31, 2025)***

On January 20, 2025, the Company granted a total of 809,712 RSUs and 809,712 performance share units (“PSUs”) under its Omnibus Equity Incentive Plan to certain executives and employees.

On February 11, 2025, the Company’s Pacifica Facility received its Control Union Medical Cannabis Standard (“CUMCS”) Equivalency Medical Cannabis, Good Agricultural Practices (“IMC-G.A.P.”) certification.

On March 3, 2025, the Company entered into a purchase and sale agreement (“PSA”) with Medipharm Labs Inc. to acquire an operational, purpose-built indoor cultivation facility in Hope, British Columbia, spanning 47,500 square feet, the Cascadia Facility. Under the terms of the PSA, the purchase price for the Cascadia Facility is \$4.5 million subject to certain conditions, including the Company’s satisfactory completion of due diligence, securing financing, and approval by the Company’s board of directors. The Company plans to use the Cascadia Facility to expand its production capacity. The transaction is expected to close in the second quarter of 2025.

On March 13, 2025, the Company announced its first international shipment, to Poland, of premium dried flower.

On May 7, 2025, the Company closed a non-brokered private placement (the “Offering”) of 10,227,265 units of the Company (each, a “Unit”) at a price of \$0.44 per Unit for aggregate gross proceeds of approximately \$4,500. Each Unit consists of one common share in the authorized share structure of the Company (each, a “Common Share”), and one-half of one Common Share purchase warrant (each, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Common Share at a price of \$0.70 for a period of 24 months following the closing date of the Offering, provided that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least \$1.00 at the close of any trading day for a period of 20 consecutive trading days following the date of issuance, the expiry date of the Warrants may be accelerated by the Company to a date that is not less than 30 days after the date that notice of such acceleration is provided to the holders of the Warrants by way of a press release (the “Accelerated Expiry Date”). All Warrants that remain unexercised following the Accelerated Expiry Date shall immediately expire and all rights of holders of such Warrants shall be terminated without any compensation to such holder. In connection with the closing of the Offering, the Company paid finders’ fees to eligible finders in the aggregate amount of approximately \$100 and issued 228,335 finder warrants (the “Finder Warrants”). Each Finder Warrant is exercisable into one-half of one Common Share at a price of \$0.70 for a period of 24 months following the closing date of the Offering, subject to the Accelerated Expiry Date. The Finder Warrants are subject to a hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.

On May 15, 2025, the Company announced the appointment of Glen Ibbott as Interim Chief Financial Officer (“CFO”) effective immediately.

On May 22, 2025, the Company announced the removal of all conditions precedent, related to its previously announced purchase and sale agreement (the “PSA”) with Medipharm Labs Inc. for an operational, purpose-built 47,500 square foot indoor cultivation facility in Hope, British Columbia, the Cascadia Facility.

On June 5, 2025, the Company announced the closing of its acquisition of an operational, purpose-built 47,500 square foot indoor cultivation facility in Hope, British Columbia. The Cascadia Facility spans 47,500 square feet of purpose-built indoor capacity and is equipped with advanced cultivation technology, supporting Rubicon Organics’ strategy to expand its premium product offerings and increasing supply to meet rising demand.

On July 2, 2025, the Company announced the launch of its new 1964 Supply Co.™ (“1964”) All-in-One (“AIO”) Full Spectrum Extract (“FSE”) Resin Vapes into the Canadian market. The first AIO release is expected to feature Comatose, 1964’s best-selling 510 vape SKU, in a 0.5 gram format that allows for an attractive price point and broad consumer accessibility. The product launched

in British Columbia and was rolled out to most major provinces across Canada (excluding Quebec) in the following months.

On July 31, 2025, at the Company's AGSM, Doris Bitz, Len Boggio, Margaret Brodie, Michael Detlefsen, Ian Gordon, Jesse McConnell, John Pigott, and Karen Proud were elected as directors of the Company (together the "Board") for the ensuing year until the next annual meeting of the Company.

On July 31, 2025, at the Company's AGSM, the shareholders approved an amendment to the Company's existing Omnibus Equity Incentive Plan, such that 8,960,179 common shares be reserved for issuance thereunder.

On July 31, 2025, at the Company's AGSM, the shareholders approved the appointment of PricewaterhouseCoopers LLP as the Company's auditors for the ensuing year with the Company's directors authorized to fix their remuneration

On October 20, 2025, the Company announced the Cascadia facility, located in Hope, British Columbia, has received its license to cultivate, process, and store cannabis from Health Canada. The license has enabled Rubicon to begin cultivating cannabis at the 47,500 square foot, purpose-built indoor facility, already equipped with advanced cultivation technologies. This new facility is expected provide an additional 4,500 kg of production capacity, representing an incremental 40% on existing capacity, bringing its total annual capacity to 15,500 kg of premium cannabis.

On October 28, 2025, the Company announced the publication of its fifth annual Environmental, Social and Governance Report.

On November 10, 2025, the Company announced it has entered into additional credit agreements (the "Credit Agreements") pursuant to which it has borrowed up to an aggregate of \$4,000 from Community Savings Credit Union ("CSCU"). The Credit Agreements consist of a \$3,000 capital loan with a term of five years, with an amortization period of ten years and bears interest at a rate of 6.79% per annum and a \$1,000 line of credit which bears interest at a rate of CSCU Basic Lending Rate plus 5.50% calculated on a monthly basis. The Credit Agreements are secured against the Cascadia Facility and are planned to be used to fund margin accretive projects at its Pacifica and Cascadia Facilities. The funds were received on December 2, 2025.

On November 12, 2025, the Company announced the appointment of Glen Ibbott, previously Interim CFO, as permanent CFO, effective immediately.

On November 17, 2025, the Company announced its extraordinary performance at the 2025 KIND Awards, earning multiple awards, including Budtender Choice for its super premium brand Simply Bare™ Organic and Brand of the Year for 1964 Supply Co.™.

### ***Recent Developments (January 1, 2026, to March 23, 2026)***

On January 15, 2026, the Company granted a total of 1,002,773 RSUs and 1,002,773 performance share units ("PSUs") under its Omnibus Equity Incentive Plan to certain executives and employees.

On February 19, 2026, the Company announced its first harvest at the Cascadia facility. The facility is now fully planted and these harvests are expected to be monetized in Q2, with production quality projected to reach flagship-brand standards by mid-2026.

## **DESCRIPTION OF THE COMPANY'S BUSINESS**

### **Summary**

Rubicon Organics is a Licensed Producer under the Cannabis Act, focused on cultivating and selling premium and super-premium cannabis products for the recreational-use and medical markets in Canada and international medical markets.

The Company owns and operates two complementary production facilities in British Columbia, each playing a distinct and important role in Rubicon's ability to deliver consistent, high-quality cannabis at scale. The Pacifica Facility is a 125,000 sq. ft. high-tech greenhouse located on a 20-acre property in Delta, British Columbia. Acquired in September 2017 and licensed in February 2019, the Pacifica Facility has been fully planted since March 2020, the Company continues to focus on refining cultivation quality and yield. This facility serves as the Company's primary production hub; housing cultivation, processing, packaging, and distribution operations that support Rubicon's national sales network. In June 2025, Rubicon Organics acquired the Cascadia Facility, a purpose-built 47,500 sq. ft. indoor cultivation facility located in Hope, British Columbia, which received its Health Canada license in October 2025. Cascadia's controlled indoor environment is purpose-designed for cultivating premium cannabis, enabling a high degree of precision and consistency in our growing operations.

Rubicon Organics has developed a House of Premium Brands portfolio and established sales channels with cannabis products distributed nationally throughout Canada and is expanding into international markets. Rubicon has become a trusted brand and partner to customers through the supply chain and is committed to consistently delivering a quality experience at all touchpoints.

Over the next 12 months, the Company is focused on bringing the Cascadia Facility to full operational capacity, which is expected to meaningfully expand the volume and variety of premium products available for sale. This additional capacity is expected to fuel continued revenue growth, support the expansion of our product portfolio in the Canadian recreational and medical markets, and accelerate our ability to serve patients in international markets where demand for certified premium cannabis continues to grow.

## **Products and Services**

### *Canada*

Through the Company's wholly-owned subsidiary, RHC, the Pacifica and Cascadia Facilities are fully licensed to cultivate, process and sell cannabis products from its 125,000 sq. ft. high-tech greenhouse and 47,500 sq. ft. indoor cultivation facility respectively.

### *Organic Certification*

In July 2019, the Company received its organic certification at the Pacifica Facility from the Fraser Valley Organic Producers Association ("FVOPA") to become an organic certified cannabis producer and subsequently completed its first commercial scale harvest in October 2019. The Company has maintained its organic certification for its Pacifica Facility since.

### *Brands*

**Simply Bare™** is Rubicon Organics' flagship super-premium brand and one of Canada's few certified organic, living-soil cannabis producers. The brand focuses on cultivating unique and rare phenotypes that deliver terpene-rich flower with exceptional aroma, flavour, and potency. Grown in living organic soil and hand-tended using certified organic methods, Simply Bare provides a clean, high-quality cannabis experience.

**1964 Supply Co™** is our largest brand by revenue, offering a portfolio centered on classic, legacy cannabis strains. The brand reflects the heritage of traditional cannabis, using time-tested cultivation inputs and sustainable growing practices to produce high-quality products with familiar, potent genetics. Positioned within the premium segment, 1964 appeals to consumers looking for authenticity and continuity with cannabis' legacy culture, delivering consistently strong performance in the market.

**Wildflower™** is our wellness brand owned by Rubicon Organics in Canada. The brand was designed to meet the various needs of wellness consumers from pain management to anxiety relief and sleep aid. Wildflower™ focuses on the wellness segment of the cannabis industry, offering topical and ingestible cannabinoid-based products derived from clean, carefully cultivated sources. With an emphasis on CBD, natural, simple and plant-based ingredients, Wildflower™ bridges the gap between cannabis products and everyday wellness.

**Homestead Cannabis Supply™** is our mainstream offering, designed to provide consumers with competitively priced quality cannabis. The brand serves as a strategic channel for high-quality flower that does not meet the elevated specifications of Rubicon's premium portfolio, enabling us to optimize biomass utilization and cash generation.

### *Customers*

Rubicon offers a broad portfolio of SKUs available for sale across Canada, with extensive coverage of the addressable market. The Company has direct supply agreements in place with the British Columbia Liquor Distribution Branch ("BCLDB"), the Alberta Gaming, Liquor and Cannabis Commission ("AGLC"), the Ontario Cannabis Stores ("OCS"), the Société Québécoise du cannabis ("SQDC"), Cannabis NB ("CNB"), the Yukon Liquor Corporation ("YLC") and sells directly to Manitoba Liquor & Lotteries ("MBLL"), the Northwest Territories Liquor, Cannabis Commission ("NTLCC"), the Newfoundland Liquor Corporation ("NLC"), Nova Scotia Liquor Corporation ("NSLC"), and the PEI Cannabis

Management Corporation (“PEICMC”). The Company also has distribution agreements in place with Saskatchewan-based distributors, who supply its products to provincial distributors and retailers. Additionally, the Company provides products to medical cannabis distributors.

## **Environment, Social and Governance (“ESG”)**

Rubicon’s vision is to be the most trusted house of premium cannabis brands—creating elevated experiences for people everywhere. The Company’s mission is to build brands people believe in by delivering elevated experiences in all Rubicon does. Through uncompromising quality, purposeful innovation, and trusted partnerships, the Company creates products and relationships that enrich lives and help shape the future of cannabis. These statements combined speak to our obsession with quality, our passion for the cannabis industry, and our ambition for positive impact on our industry our people, our consumers, and our partners in the value chain.

The Company has developed an ESG strategy with four pillars that outline high-level objectives to address material topics most relevant each focus areas. The four focus areas include:

- Governance
- Environment
- People
- Community

Rubicon Organics was the first cannabis company in the world to release an ESG report (“ESG Report”) and expects to continue to take an ESG leadership position in the cannabis sector. The fifth annual ESG report was published in October 2025. The ESG Report reflects the Company’s determination to embed sustainability in a formal manner through its operations and supply chain, and to communicate its progress with stakeholders in a transparent and authentic manner.

## **Modern Slavery Statement**

In alignment with the *Fighting Against Forced Labour and Child Labour in Supply Chains Act* (“Supply Chains Act”), the Company issued its second Modern Slavery Statement in May 2025.

### ***United States***

As of May 15, 2020, the Company no longer performed any services to the cannabis industry in the US and all subsidiaries were dissolved by December 1, 2020. Prior to this time, the Company was in compliance with all applicable licensing requirements and the regulatory frameworks enacted in its operations in both Washington and California.

## **Code of Ethics**

The Company’s code of ethics is reviewed and approved annually by the Nomination and Governance Committee and is posted on our website.

## **Specialized Skill and Knowledge**

All aspects of the Company’s business require specialized skills and knowledge. Such skills and knowledge include the areas of cultivation and growing of cannabis, and specifically the unique greenhouse and indoor growing agricultural skills required for the cultivation of organic cannabis in compliance with the Cannabis Act, directives issued by Health Canada and the stringent requirements of FVOPA, a leading organization in organic certification in Canada.

Rubicon Organics’ experienced growing team and quality assurance team are focused on generating the highest quality and most consistent product that meets and exceeds the regulatory requirements. The Company practices strict regulatory compliance and maintains a high level of quality assurance and testing protocols to achieve customer satisfaction. In addition, the Company implements proven measures for additional certainty regarding the purity and safety of the cannabis it produces.

Rubicon Organics’ consumer packaged goods (“CPG”) expertise in areas of inventory management, market research, innovation, and brand building are expected to allow the Company to successfully distribute high quality cannabis products to the Canadian market. The Company’s disciplined consumer focused approach and CPG experience are also supporting

growth in a constantly evolving marketplace.

Management is composed of individuals who have extensive expertise in the cannabis and consumer packaged goods industry, complemented by an experienced Board of Directors (the “**Board**”) with professionals from various relevant industries. See “Directors and Officers” for additional information.

### **Competitive Conditions**

As of the date of this AIF, Health Canada has a total of 1,001 companies on its list of license holders which includes duplicate sites for some license holders. There are also a number of unlicensed growers of cannabis who have or plan to seek to obtain some form of license under the Cannabis Act. Health Canada requires new license applicants to have a fully built site that meets all the requirements of the Cannabis Regulations at the time of their application. The Company believes that the stringent application and compliance requirements may prove too onerous or expensive for some applicants.

In addition, there are illegal growers and retailers operating in the illicit market that, while operating illegally, still act as competitors to the Company by diverting customers away from the legal cannabis market.

The Company believes that its leadership team, brand strategy and commitment to super-premium and premium organic cannabis products is expected to enable the Company to establish and retain a strong and sustainable position in the market. See “Risk Factors” for additional information.

### **Components**

The Cultivation & Processing Licenses allowed the Company to bring in an extensive library of unique and proven genetic starting materials, including unique stabilized cultivars previously developed in the medical cannabis market, as well as actively breed new genetics to continually expand this library. These genetic assets are expected to be instrumental in Rubicon Organics’ launch of new strains for the Canadian and international medical markets.

The equipment used to cultivate and process cannabis is specialized but is readily available and not specific to the cultivation of cannabis. The Company does not anticipate any difficulty in obtaining equipment as needed.

### **Intangible Properties**

The ownership and protection of the Company’s intellectual property is key to the Company’s continued success. The Company’s intangible assets are protected through trade secrets, technical know-how and proprietary information. The Company’s intellectual property is protected by seeking and obtaining registered protection (including trademarks and patents) where possible, developing and implementing standard operating procedures and entering into agreements with parties that have access to the Company’s inventions, trade secrets, technical know-how and proprietary information such as business partners, collaborators, employees and consultants, to protect the Company’s confidentiality and ownership of its intellectual property. The Company preserves the integrity and confidentiality of its inventions, trade secrets, trademarks, technical know-how and proprietary information by maintaining physical security of the Company’s premises and physical and electronic security of the Company’s information technology systems.

### **Employees**

As at December 31, 2025, the Company had a total of 263 full-time employees and 3 part-time employees.

### **Canadian Regulatory Overview**

On April 13, 2017, the Government of Canada introduced Bill C-45 to amend the *Controlled Drugs and Substances Act* (which governs the Access to Cannabis for Medical Purposes Regulations (“**ACMPR**”), the *Criminal Code* (Canada), the *Narcotic Control Regulations* (“**NCR**”) and other related legislation to legalize and regulate the use of cannabis for recreational purposes. The Cannabis Act, the Cannabis Regulations, and related ancillary amendments to other legislation, came into effect October 17, 2018.

Pursuant to the Cannabis Act, individuals over the age of 18 are able to purchase fresh cannabis, dried cannabis, cannabis oil, and cannabis plants or seeds and are able to legally possess up to 30 grams of dried cannabis, or the dried flower equivalent in other products. The Cannabis Act also permits households to grow a maximum of four cannabis plants. This

limit applies regardless of the number of adults that reside in the household. In addition, the Cannabis Act provides provincial, territorial, and municipal governments the authority to prescribe regulations regarding retail and distribution, as well as the ability to alter some of the existing baseline requirements, such as increasing the minimum age for purchase and consumption.

On July 11, 2018, the Government of Canada published the Cannabis Regulations in the Canada Gazette, Part II, to support the coming into force of the Cannabis Act, along with amendments to the NCR and certain regulations under the *Food and Drugs Act* (Canada). The Cannabis Regulations, among other things, outline the rules for the legal cultivation, processing, research, testing, distribution, sale, importation and exportation of cannabis and hemp in Canada, including the various classes of licenses that can be granted, and set standards for cannabis and hemp products made available for legal sale subsequent to October 17, 2018. Previously, medical cannabis was largely regulated by the ACMPR but, on October 17, 2018, the Cannabis Act and the Cannabis Regulations replaced this regime.

On December 22, 2018, the Government of Canada published the draft of the *Regulations Amending the Cannabis Regulations* (the “**Further Regulations**”). The Further Regulations amend the Cannabis Act and Cannabis Regulations to, among other things, allow the production of cannabis extracts (including concentrates), edibles and topicals in addition to the currently permitted product forms. The final version of the Further Regulations was published on June 13, 2019 and came into force on October 17, 2019.

On October 19, 2020, the Canadian Chamber of Commerce announced the launch of an industry-led review of the Cannabis Act to provide recommendations on how the federal government should improve Canada’s legislative and regulatory frameworks for cannabis. Following the completion of this review, the government has undertaken a series of consultations and regulatory amendments, as further described below.

On March 25, 2023, Health Canada issued a 60-day notice of intent to receive feedback on potential amendments to the Cannabis Regulations around licensing, security measures, production and packaging and labelling requirements, and record-keeping for license holders. This is in addition to the legislative review of the Cannabis Act, focusing on the societal impacts of cannabis legislation, which is under review.

On June 8, 2024, the Government of Canada published proposed changes to the Cannabis Regulations and other connected regulations in the Canada Gazette, Part I, initiating a 30-day feedback period on the proposed changes. Proposed changes include changes to packaging & labelling requirements, such as allowing for transparent packaging for dried cannabis, reporting & record keeping requirements, such as the removing the requirement to track non-viable plant waste, and other administrative requirements, such as increasing the responsibilities and number of Alternate Quality Assurance Person(s) (“**AQAP**”). These amendments were enacted by Health Canada on March 12, 2025.

On March 12, 2025, Health Canada initiated a consultation period, until June 5, 2025, to explore the possibility of creating a pathway for CBD products to be classified as health products for both humans and animals, without the need for a prescription.

On May 5, 2025, Health Canada announced that effective April 1, 2025, license holders are no longer required to report on plant trimmings for whole and vegetative cannabis plants. The unit of measurement for unpackaged seeds has also changed from kilograms to the count of seeds (whole numbers).

On July 22, 2025, Health Canada announced that effective April 1, 2025, license holders are no longer required to submit a corrective and preventive action (CAPA) plan for minor observations in a cannabis inspection report. However, they are still required to develop and implement a CAPA plan for minor observations and are still required to submit a CAPA plan for major and critical observations.

On August 19, 2025, Health Canada announced that new cannabis applications are subject to service standards determined by Health Canada. In the screening stage, a service standard of 30 business days applies. In the following review stage, a service standard of 80 business days applies. These service standards don’t include the time spent waiting for the applicant to respond to the information requests.

On December 17, 2025, Health Canada published the new Controlled Substances Regulations, which required amendments to the Cannabis Regulations related to drugs containing cannabis and test kits containing cannabis. These changes are anticipated to come into force on October 1, 2026.

### Licenses, Permits and Authorizations

The Cannabis Regulations establish six classes of licenses:

- Cultivation licenses;
- Processing licenses;
- Analytical testing licenses;
- Sales licenses;
- Research licenses; and
- Cannabis drug licenses.

The Cannabis Regulations also create subclasses for cultivation licenses (standard cultivation, micro-cultivation, and nursery) and processing licenses (standard processing and micro-processing). Different licenses and each sub-class therein, carry differing rules and requirements that are intended to be proportional to the public health and safety risks posed by each license category and each sub-class. Licenses issued pursuant to the Cannabis Regulations are valid for a period of no more than five years. The Cannabis Regulations permit cultivation license to be issued for both outdoor and indoor cultivation of cannabis, however no licensed activities can take place in a “dwelling-house”.

### Security Clearances

The Cannabis Act and Cannabis Regulations require several individuals to hold a valid security clearance, including directors, officers, and large shareholders of the licensee, including officers and directors of those companies who can exert direct control over the licensee, those who hold key positions, including the Responsible Person/Alternate Responsible Person, the Head of Security/Alternate Head of Security, the Master Grower/Alternate Master Grower and the Quality Assurance Person/Alternate Assurance Person(s) and anyone else specified by the Minister. Under the Cannabis Regulations, the Minister may refuse to grant security clearances to individuals with associations to organized crime or with past convictions for, or an association with, drug trafficking, corruption, or violent offences. Individuals who have histories of nonviolent, lower-risk criminal activity (for example, simple possession of cannabis, or small-scale cultivation of cannabis plants) are not precluded from participating in the legal cannabis industry, and the grant of security clearance to such individuals is at the discretion of the Minister and such applications are reviewed on a case-by-case basis.

### Cannabis Tracking System

Under the Cannabis Act, the Minister is authorized to establish and maintain a national cannabis tracking and licensing system (the “CTLS”). The CTLS has since been established to create a seed to sale tracking system to track cannabis throughout the supply chain to help prevent diversion of cannabis into, and out of, the illegal market. Under this tracking system, certain LPs are required to submit monthly reports to Health Canada, among other things. The information required to be reported is extensive.

### Products

The Cannabis Regulations set out the requirements for the sale of cannabis products at the retail level and permit the sale of dried cannabis, cannabis oil, fresh cannabis, cannabis plants and cannabis plant seeds, including in such forms as “pre-rolled” and in capsules. The Further Regulations permit and set out the requirements for the sale of cannabis edibles, cannabis topicals and cannabis extracts (including replacing the requirements for cannabis oil). The THC content and serving size of cannabis products is limited by the Cannabis Regulations and the Further Regulations, as applicable.

### Advertising and Promotion

The Cannabis Act prohibits the promotion of cannabis, cannabis accessories or services related to cannabis, including, but not limited to:

- by communicating information about its price or distribution;
- by doing so in a manner that there are reasonable grounds to believe could be appealing to young persons;
- by means of a testimonial or endorsement, however displayed or communicated;
- by means of the depiction of a person, character, or animal, whether real or fictional; or
- by presenting it or any of its brand elements in a manner that associates it or the brand element with, or evokes a

positive or negative emotion about or image of, a way of life such as one that includes glamour, recreation, excitement, vitality, risk or daring.

The Cannabis Act does provide exceptions to these prohibitions in limited circumstances, including when the promotion is by means of an informational or brand-preference promotion and as long as that promotion is displayed in a manner that it cannot be viewed by people under the age of 18. Various provinces and territories have added additional restrictions on the promotion of cannabis which are significantly more strict, including increasing the age restrictions.

### Packaging and Labelling

The Cannabis Regulations set out requirements pertaining to the packaging and labelling of cannabis products. Cannabis package labels must include specific information, such as:

- product source information, including the class of cannabis and the name, phone number, and email of the cultivator;
- a mandatory health warning, rotating between Health Canada’s list of standard health warnings;
- the Health Canada standardized cannabis symbol; and
- information specifying THC and CBD content.

A cannabis product’s brand name may only be displayed once on the principal display panel, or if there are separate principal display panels for English and French, only once on each principal display panel. It can be in any font style and any size, so long as it is equal to or smaller than the health warning message. The font must not be in metallic or fluorescent colour. In addition to the brand name, only one other brand element can be displayed.

The interior surface and exterior surface of any container in which a cannabis product is packaged cannot have any embossing, texture, foil, or cut outs. Additionally, packages must be child-resistant and tamper-proof.

### Cannabis for Medical Purposes

Part 14 of the Cannabis Regulations sets out the regime for medical cannabis, which includes rules for non-medical use, to improve patient access, and reduce the risk of abuse within the medical access system. Patients who have the authorization of their healthcare provider have access to cannabis, either purchased directly from a federally licensed producer, or by registering to produce a limited amount of cannabis for their own medical purposes or designating someone to produce cannabis for them.

### Provincial Regulatory Regimes

While the Cannabis Act provides for the regulation by the Canadian federal government of, among other things, the commercial cultivation and processing of cannabis and the sale of medical cannabis, the various provinces and territories of Canada regulate certain aspects of adult use cannabis, such as distribution, sale, minimum age requirements, places where cannabis can be consumed, and a range of other matters.

Provincial and territorial governments in Canada have implemented varying regulatory regimes for the distribution and sale of cannabis for recreational or “adult-use” purposes, including a mix of public, private and hybrid distribution and sale models. There is no guarantee that the provincial and territorial frameworks supporting the legalization of cannabis for recreational use in Canada will continue on their current terms, or at all, or will not be amended or supplemented by additional legislation.

The Government of Canada introduced new penalties under the *Criminal Code* (Canada) in connection with the coming into effect of the Cannabis Act and the Cannabis Regulations, including penalties for the illegal sale of cannabis, possession of cannabis over the prescribed limit, production of cannabis beyond personal cultivation limits, taking cannabis across the Canadian border, giving, or selling cannabis to a youth and involving a youth to commit a cannabis-related offence.

### International Regulations

On February 11, 2025, the Company's Pacifica Facility received its CUMCS Equivalency IMC-G.A.P. certification. Obtaining the Certification provides documented evidence that Rubicon Organics has met strict international standards for quality and consistency in the cultivation, harvest and primary processing of cannabis needed for export of cannabis inputs to certain jurisdictions, including Israel, certain European countries and Australia, for further processing into finished goods via a Good Manufacturing Practices ("GMP") certified production facility.

Further, as the Company has begun international sale and distribution of its' products, these transactions are governed by the corresponding regulatory requirements relating to the export and lawful sale of products in those international jurisdictions.

### **DIVIDENDS AND DISTRIBUTIONS**

As of the date of this AIF, the Company has not declared dividends on its Common Shares. The Company currently intends to reinvest all future earnings in order to finance the development and growth of its business. As a result, the Company does not intend to pay dividends on its Common Shares in the foreseeable future. Any future determination to pay dividends will be at the discretion of the Board and is expected to depend on the financial condition, business environment, operating results, capital requirements, and any contractual restrictions on the payment of dividends and any other factors that the Board deems relevant.

### **DESCRIPTION OF CAPITAL STRUCTURE**

The authorized capital of the Company consists of an unlimited number of Common Shares. As of the date hereof, there are 67,578,916 Common Shares outstanding.

Holders of Common Shares are entitled to receive notice of, attend, and vote at meetings of the shareholders. Each Common Share carries the right to one vote. Holders of Common Shares shall, in the absolute discretion of the directors, be entitled to receive non-cumulative dividends as may be declared in respect of the Common Shares then issued and outstanding. The directors of the Company shall be at liberty to declare dividends on any one or more classes of shares to the exclusion of any other class or classes of shares in the Company entitled to dividends, and no holder of any class of shares shall be entitled to receive dividends *pari passu* with, or in priority to, the holders of any other class or classes of shares of the Company entitled to receive dividends. In the event of the liquidation, dissolution or winding up of the Company or other distribution of assets of the Company among its shareholders to wind-up its affairs or on a reduction of capital the holders of Common shares shall be entitled to receive equally, on a per share basis, the amount paid up thereon together with any declared but unpaid dividends and any remaining property or assets of the Company.

The Common Shares do not have pre-emptive rights or exchange rights and are not subject to redemption, retraction, purchase for cancellation or surrender provisions. There are no sinking or purchase fund provisions, no provisions permitting or restricting the issuance of additional securities, and there are no provisions which are capable of requiring a security holder to contribute additional capital. For a description of the Company's dividend policy, see "Dividends and Distributions".

Provisions as to the modification, amendment or variation of the rights attached to the Common Shares are contained in the Company's Articles and the BCBCA. Generally speaking, substantive changes to the authorized share structure require the approval of the Company's shareholders by special resolution (at least two-thirds of the votes cast).

## ESCROWED SECURITIES

The Company had no escrowed securities outstanding as at December 31, 2025.

## MARKET FOR SECURITIES

### Trading Price and Volume

The outstanding Common Shares are traded on the TSX-V under the trading symbol “ROMJ”.

The following table sets forth the reported intraday high and low prices and monthly trading volumes of the Common Shares from January 2025 to December 2025.

Period	High Trading Price	Low Trading Price	Volume
January 2025	\$0.50	\$0.33	661,932
February 2025	\$0.44	\$0.33	521,091
March 2025	\$0.55	\$0.40	1,087,644
April 2025	\$0.59	\$0.43	666,894
May 2025	\$0.50	\$0.39	1,637,818
June 2025	\$0.46	\$0.40	444,118
July 2025	\$0.52	\$0.43	885,524
August 2025	\$0.70	\$0.44	3,663,654
September 2025	\$0.73	\$0.56	1,186,572
October 2025	\$0.65	\$0.46	2,464,642
November 2025	\$0.55	\$0.41	1,765,994
December 2025	\$0.54	\$0.42	1,235,161

On March 23, 2026, the closing price per Common Share on the TSX-V was \$0.49.

### Prior Sales

The following tables summarizes the issuances of securities convertible or exchangeable into Common Shares, for the year ended December 31, 2025.

#### Share Based Awards

Date of Issuance	Description of Transaction	Price per Security <sup>(1)</sup>	Number of Securities
January 20, 2025	Restricted Share Unit	\$0.39	809,712
January 20, 2025	Performance Share Unit	\$0.39	809,712
July 31, 2025	Deferred Share Unit	\$0.44	1,024,576

(1) Represents the closing share price of the Company on the date of issuance.

## DIRECTORS AND EXECUTIVE OFFICERS

The following table sets out, for each of the Company’s directors and executive officers, the person’s name, province or state and country of residence, position with us, principal occupation, and the date on which the person became a director or executive officer. The Company’s directors are expected to hold office until the Company’s next annual general meeting of shareholders. The Company’s directors are elected annually and, unless re-elected, retire from office at the end of the next annual general meeting of shareholders. As a group, the directors and executive officers beneficially own or control, directly or indirectly, a total of 29,135,803 Common Shares, representing 43% of the Common Shares outstanding as at the date of this AIF.

## Directors and Executive Officers at the date of this AIF

Name and Province or State and Country of Residence	Position with the Company	Age	Director/Officer Since	Principal Occupation
Doris Bitz <sup>(1)(2)(5)</sup> Ontario, Canada	Director	62	October 16, 2023 <sup>(8)</sup>	Former President, Retail of Dessert Holdings and a previous marketing executive at top-tier CPG companies including PepsiCo Canada and General Mills Canada.
Len Boggio <sup>(2)(6)</sup> British Columbia, Canada	Director	71	September 14, 2023	Retired partner of PricewaterhouseCoopers LLP since 2012. Independent director of several publicly listed companies including current director of Equinox Gold Corp. and Titan Mining Corporation. Mr. Boggio is a Fellow of the Chartered Professional Accountants of British Columbia (“CPABC”) and was a past president of the Institute of Chartered Accountants of BC, now CPABC, and the Canadian Institute of Chartered Accountants, now CPA Canada.
Margaret Brodie British Columbia, Canada	Chief Executive Officer (“CEO”) and Director	48	May 24, 2018	CEO of the Company since February 15, 2024, previously Interim CEO from January 1, 2023, and CFO since November 10, 2016. Ms. Brodie is a Board member Cannabis Council of Canada since May 2024. Ms. Brodie served as Director of Plata Latina Minerals Corp., a mining company (2015-2024), and formerly CFO (2012-2016). In addition, Ms. Brodie has acted as CFO for Riva Gold Corporation, a mining company, until its purchase by Arizona Mining Inc. in 2013 (2010-2013) and Armor Minerals Corp (2015), a mining company. Prior to that, Ms. Brodie was a Senior Manager with KPMG LLP in Vancouver, British Columbia and London, United Kingdom.
Michael Detlefsen <sup>(3)(4)</sup> Ontario, Canada	Director	62	March 20, 2023	Managing Director of Pomegranate Capital Advisors, an active investor advisory firm based in Toronto. Previously, Mr. Detlefsen has held senior executive roles at Air Canada, Bell Canada/BCI, Maple Leaf Foods and Ceres Global Ag Corp. and has worked in the consulting practices of Monitor Company and PwC, as well as for the Government of Canada.
Ian Gordon <sup>(4)(5)</sup> Ontario, Canada	Director	64	September 14, 2023	Former Senior Vice President of Loblaw Brands Limited and previously held senior marketing and sales roles at leading CPG companies including Unilever and International Multifoods, and President of ACLC Advertising. Mr. Gordon is board chair of Canadian Sport Institute of Ontario, a board member of Recycle BC, Multi-Material Stewardship Western, and The Canada Plastics Pact.

Jesse McConnell British Columbia, Canada	Director	49	September 4, 2024 <sup>(9)</sup>	Co-Founder and CEO of the Company between May 20, 2015 until December 31, 2022. Mr. McConnell is an entrepreneur, investor and cannabis expert who has worked in the premium cannabis industry in Canada and the US for over two decades. Previously, Mr. McConnell co-founded Whistler Medical Marijuana Corp., which was eventually acquired by Aurora Cannabis Inc. in 2019.
John Pigott <sup>(4)(5)</sup> Ontario, Canada	Director	69	May 24, 2018	Chief Executive Officer of Morrison Lamothe Inc., since June 1989. Previously Chief Executive Officer of Club Coffee L.P., a manufacturing company, in Etobicoke, Ontario between February 2007 and July 2024.
Karen Proud <sup>(4)(7)</sup> Ottawa, Canada	Director	55	September 14, 2023	Ms. Proud has been President and Adjudicator of the Office of the Grocery Sector Code of Conduct since March 17, 2025. She previously held senior leadership roles within national industry trade associations across Canada's agri-food, consumer products, and retail sectors, and spent a decade as a regulator at Health Canada. She has also served on multiple non-profit industry boards in Canada and internationally.
Melanie Ramsey British Columbia, Canada	Chief Operating Officer ("COO")	49	November 14, 2022	VP Marketing & Innovation of the Company from August 2018, Chief Commercial Officer from November 2022 until promotion to Chief Operating Officer effective January 1, 2025. Ms. Ramsey has over 25 years of Global CPG experience with companies including Diageo and Beiersdorf throughout Africa, Asia, Europe and North America.
Glen Ibbott British Columbia, Canada	Chief Financial Officer ("CFO")	63	May 15, 2025	CFO of the Company since November 12, 2025, previously Interim CFO since May 15, 2025. Mr. Ibbott has over 25 years of leadership experience in publicly-traded life sciences and cannabis companies, most notably serving as CFO for Aurora Cannabis from 2017 to 2024.

- 
- (1) Chair of the Board of Directors
  - (2) Member of the Audit Committee.
  - (3) Chair of the Audit Committee.
  - (4) Member of the Nomination and Governance Committee.
  - (5) Member of the Compensation Committee.
  - (6) Chair of the Nomination and Governance Committee.
  - (7) Chair of the Compensation Committee.
  - (8) Elected as a director of the Company following the AGM on September 14, 2023 and appointed to the Board of Directors on October 16, 2023 following being granted security clearance by Health Canada.
  - (9) Elected as a director of the Company following the AGM on July 31, 2024 and appointed to the Board of Directors on September 4, 2024 following being granted security clearance by Health Canada.

## **Cease Trade Orders or Bankruptcies**

None of the directors or executive officers has, within the 10 years prior to the date of this AIF, been a director, chief executive officer or chief financial officer of any company (including us) that, while such person was acting in that capacity (or after such person ceased to act in that capacity but resulting from an event that occurred while that person was acting in such capacity) was the subject of a cease trade order, an order similar to a cease trade order, or an order that denied the Company access to any exemption under securities legislation, in each case for a period of more than 30 consecutive days.

Except as noted below, none of the directors or executive officers have, within the 10 years prior to the date of this AIF, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets, been a director or executive officer of any company, that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Mr. Boggio was a director of Pure Gold Mining Inc. (Pure Gold) until March 30, 2023. Pure Gold owned the Madsen Mining property, located near Red Lake Ontario. After redeveloping the property and processing facilities, Pure Gold experienced significant start up and operational difficulties. Consequently, on October 31, 2022, Pure Gold applied for and received an initial order for creditor protection from the Supreme Court of British Columbia (Court) under the Companies' Creditors Arrangement Act ("CCAA"). On November 10, 2022, the Court approved a Sales and Investment Solicitation Process Order, among other relief. On March 30, 2023, Pure Gold requested and the Court approved the appointment of a Chief Administrative Officer, following which all members of the Pure Gold board of directors resigned. Pure Gold's common shares were then suspended from trading and the company was subsequently acquired by West Lake Gold Mines on June 16, 2023 under the CCAA proceedings.

Mr. Detlefsen served as a member of the Board of Directors of Blueday Technology AS (Blueday Technology), a privately held company based in Sandnes, Norway, until January 22, 2026. On the same date, Blueday Technology was subject to a court-mandated restructuring proceeding under applicable Norwegian law due to a cessation of funding by its principal shareholder. On January 26, 2026, Blueday Technology was declared bankrupt, and its bankruptcy estate was subsequently acquired by NOS Elektro, a subsidiary of NOS Group AS.

## **Penalties or Sanctions**

None of the Company's directors or executive officers or any shareholder holding sufficient securities of the Company to affect materially the control of the Company has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority or been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor making an investment decision.

## **Conflicts of Interest**

To the best of the Company's knowledge, there are no known existing or potential material conflicts of interest among the Company and the Company's directors, officers or other members of management of the Company as a result of their outside business interests except that certain of the Company's directors and officers serve as directors, officers or advisors of other companies, and therefore it is possible that a conflict may arise between their duties to the Company and their duties as a director, officer or advisor of such other companies.

## **LEGAL PROCEEDINGS AND REGULATORY ACTIONS**

The Company and its subsidiaries may from time to time be involved in legal proceedings of a nature considered normal to its business. The only litigation in which the Company is currently involved, or have been involved since the beginning of the most recently completed financial year, individually or in the aggregate, is the Roberts Claim, which is not material to our consolidated financial condition or results of operations.

There have been no: (i) penalties or sanctions imposed against the Company by a court relating to securities legislation or by a securities regulatory authority during the most recently completed financial year; (ii) penalties or sanctions imposed

by a court or regulatory body against the Company that would likely be considered important to a reasonable investor in making an investment decision; and (iii) settlement agreements the Company entered into before a court relating to securities legislation or with a securities regulatory authority during the most recently completed financial year.

### **INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS**

To the best of the Company's knowledge, there are no known existing or potential material conflicts of interest, nor have there been any known existing or potential material conflicts of interest during the three most recently completed financial years, among the Company and the Company's directors, officers or other members of management of the Company as a result of their outside business interests except that certain of the Company's directors and officers serve as directors, officers or advisors of other companies, and therefore it is possible that a conflict may arise between their duties to the Company and their duties as a director, officer or advisor of such other companies.

### **TRANSFER AGENT AND REGISTRAR**

The transfer agent and registrar for the Common Shares is Odyssey Trust Company in Vancouver, British Columbia.

### **MATERIAL CONTRACTS**

Except for contracts entered into in the ordinary course of business, the only contracts entered into by the Company since the beginning of the last financial year, or before the beginning of the last financial year that is still in effect, which may be regarded as material, are the following:

- (a) the board nomination agreement with Jesse McConnell (the "**Board Nomination Agreement**").

Copies of the material contract is available under the Company's profile on the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR+") website at [www.sedarplus.ca](http://www.sedarplus.ca).

The Board Nomination Agreement provides that at any meeting of the shareholders of the Company at which the election or removal of directors to or from the Board is to be considered, Mr. McConnell is entitled, by providing more than 60 days written notice, to nominate one Board member for successive terms. Any nominee must be eligible to serve as a director of the Company pursuant to applicable corporate and securities laws, the rules, and policies of any exchange on which the Company's Common Shares are listed or quoted and other regulatory provisions to which the Company is subject. Mr. McConnell exercised his nomination right prior to the 2024 Annual General Meeting (AGM) and was successfully elected to the Board. Mr. McConnell also exercised his nomination right prior to the 2025 Annual General Meeting (AGM) and was successfully elected to the Board.

If a nominee shall be disqualified, be removed, or resign or otherwise cease to be a director of the Company, Mr. McConnell will have the right to designate a further nominee to fill the vacancy so created. The Board Nomination Agreement will automatically terminate if Mr. McConnell's ownership of the Company's issued and outstanding Common Shares decreases to below 10%.

### **INTERESTS OF EXPERTS**

PricewaterhouseCoopers LLP is the auditor of the Company. PricewaterhouseCoopers LLP is independent with respect to the Company within the meaning of the Rules of Professional Conduct of the Chartered Professional Accountants of British Columbia.

## **RISK FACTORS**

The risks and uncertainties described below are those the Company currently believes to be material, but they are not the only ones the Company faces. If any of the following risks, or any other risks and uncertainties that the Company has not yet identified or that the Company currently considers not to be material, actually occur or become material risks, the Company's business, prospects, financial condition, results of operations and cash flows could be materially and adversely affected. In that event, the market price of the Company's securities could decline, and you could lose part or all of your investment.

### **Risks Generally Related to the Company**

#### ***Challenging Global Financial Conditions***

In recent years, global financial conditions have become increasingly volatile due to events such as worldwide political unrest, pandemics, recession, the rising economic impact of tariffs, and high inflationary environment which have had an impact on global capital markets. Future crises could stem from a variety of causes, including natural disasters, geopolitical instability, pandemics, new infectious diseases or viruses, energy price changes, or supply chain disruptions. Any sudden or rapid destabilization of the global economic conditions could have negative consequences for the Company, making it difficult to access credit and capital markets. It could also affect the Company's ability to fulfill obligations to counterparts, including interest and other debt payments, ultimately having a negative impact on its financial position, cash flow, and operating results. If volatility levels continue to rise, or if global economic conditions experience a general decline, it could impact consumption patterns, financial markets, and the value and liquidity of a company's common shares, significantly affecting the company's well-being. These events may damage the Company's properties, deny the Company access to an adequate workforce, increase the cost of energy and other raw materials, temporarily or permanently close the Company's facilities, disrupt the production, supply and distribution of the Company's products, and disrupt the Company's information systems.

#### ***Tariffs and Trade Regulations***

The Company faces risks associated with the potential imposition of tariffs, which could affect its cost structure and operational efficiency. While the cannabis industry in Canada is regulated domestically, the Company may still be impacted by international trade policies and tariff changes, particularly in relation to the importation of raw materials, packaging, and equipment used in the production and distribution of cannabis products.

Tariffs on imported goods could result in higher costs for these inputs, which may lead to increased production expenses. If tariffs are imposed on cannabis products in international markets, the Company's ability to expand into or maintain operations in those markets could be adversely affected. Additionally, any shifts in the global trade environment, including changes to bilateral or multilateral trade agreements, could impact the Company's ability to source materials efficiently or hinder access to key markets for its products.

The Company continues to monitor trade developments and potential tariff changes closely. However, there is no certainty that Rubicon can mitigate the impact of tariffs through alternative sourcing strategies or pricing adjustments. Any unforeseen changes to the tariff landscape could materially affect the Company's profitability, operational flexibility, and growth prospects.

#### ***Price Compression in the Cannabis Industry***

The cannabis industry has recently experienced, and certain segments continue to experience, price compression, which may adversely impact the Company's profitability. In addition, such price compression, as well as, or together with, the oversupply of certain types of inventory in the industry, may result in the Company incurring additional impairment losses on inventory in the event the cost of our inventory exceeds its net realizable value. The continuing evolution of these market conditions represent ongoing uncertainties that may affect the Company's future financial results.

#### ***The adult-use recreational cannabis market in Canada may become oversupplied***

The Company and other cannabis producers in Canada may produce more cannabis than is needed to satisfy the collective demand of the Canadian market, and the Company may be unable to export that oversupply into other jurisdictions where cannabis use is fully legal under all applicable laws of such jurisdictions. As a result, the available supply of cannabis could

exceed demand, resulting in a significant decline in the market price for cannabis. If this were to occur, there is no assurance that the Company would be able to generate sufficient revenue from the sale of adult-use recreational cannabis to result in profitability.

***Changes in the public's perception of medical and/or adult-use cannabis could increase future regulation***

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, or elsewhere. A negative shift in the public's perception of cannabis in any applicable jurisdiction could affect future legislation or regulation. Any inability to fully implement the Company's expansion and sales strategies may have a material adverse effect on the Company's business, financial condition, and results of operations.

***The Company's industry is experiencing growth and consolidation that may cause the Company to lose key relationships and intensify competition***

The cannabis industry is undergoing growth and substantial change, which has resulted in an increase in competitors, consolidation, and formation of strategic relationships. Acquisitions or other consolidating transactions could harm the Company in a number of ways, including by losing strategic partners if they are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing the Company to expend greater resources to meet new or additional competitive threats, all of which could harm the Company's operating results. As competitors enter the market and become increasingly sophisticated, competition in the Company's industry may intensify and place downward pressure on retail prices for its products and services, which could negatively impact its profitability.

***The expansion of the medical cannabis industry may require new clinical research into effective medical therapies, when such research is new to Canada and has been restricted in some international jurisdictions***

Research in Canada and internationally regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in its early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although the Company believes that the articles, reports, and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, investors should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to medical cannabis, which could have a material adverse effect on the demand for the Company's products with the potential to lead to a material adverse effect on the Company's business, financial condition, and results of operations.

***The Company is subject to changes in Canadian laws, regulations and guidelines which could adversely affect the Company's future business, financial condition, and results of operations***

The Cannabis Act, and related ancillary amendments to other legislation, came into effect October 17, 2018. As a result, the Company's operations are subject to various laws, regulations and guidelines relating to the manufacture, management, packaging/labelling, advertising, sale, transportation, storage, and disposal of cannabis but also including laws and regulations relating to drugs, controlled substances, health and safety, the conduct of operations and the protection of the environment. Changes to such laws, regulations, and guidelines due to matters beyond the control of the Company may cause adverse effects to its operations. The Company endeavours to comply with all relevant laws, regulations, and guidelines.

The Cannabis Act may also materially and adversely affect the future business, financial condition, and results of operations of the Company, as, among other things, the legislation permits home cultivation, and implements restrictions on advertising and branding. It is possible that such developments could significantly adversely affect the future business, financial condition, and results of operations of the Company.

***Under Canadian regulations, a licensed producer of cannabis has restrictions on the type and form of marketing it can undertake which could materially impact sales performance***

The development of the Company's future business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by Health Canada. The regulatory environment in Canada limits the Company's ability to compete for market share in a manner similar to other highly regulated industries, including significant limitations on

promotion. If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company's sales and operating results could be adversely affected.

***The Company's operations are subject to environmental regulation in the jurisdictions in which it operates***

These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage, and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which is expected to require more strict standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors, and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company's operations.

Government environmental approvals and permits are currently, and may in the future be, required in connection with the Company's operations. To the extent such approvals are required and not obtained, the Company may be curtailed or prohibited from its proposed business activities or from proceeding with the development of its operations as currently proposed.

Failure to comply with applicable environmental laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage due to its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

***There is no assurance that the Company will turn profits or pay dividends***

There is no assurance as to whether the Company will sustain profitability or pay dividends. The Company has incurred and anticipates that it will continue to incur substantial expenses relating to the development and initial operations of its business and if additional capacity is identified, this would likely require the use of cash generated from its Pacifica and Cascadia Facilities to support any capital or operating expenditures required prior to a new business unit or facility becoming profitable and cashflow positive.

The payment and amount of any future dividends will depend upon, among other things, the Company's results of operations, cash flow, financial condition, and operating and capital requirements. There is no assurance that future dividends will be paid, and, if dividends are paid, there is no assurance with respect to the amount of any such dividends.

In the event that any of the Company's historical investments or operations, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such historical investments or operations in the U.S. were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under applicable legislation. This could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, affect other distributions, or subsequently repatriate such funds back to Canada.

***There are no assurances the Company's sales channels will remain accessible or that distributors will keep the Company's product listings, which if lost will impact the Company's ability to generate revenue***

The Company maintains supply agreement with each province in which it sells cannabis as well as with private distributors to deliver its products to retailers and consumers. These provincial entities and private distributors review and list the products they wish to sell in their market. While the Company maintains agreements in all major markets across Canada there are no guarantees these contracts are renewed or that these entities maintain or grow the number of product listings they currently have with the Company. Should any contract be cancelled, or any product be de-listed, there may be negative impacts on the Company's ability to sell and monetize its inventory.

***The Company's ability to continue as a going concern***

For the year ended December 31, 2025, the Company recorded a net income of \$1,051, bringing its total accumulated deficit to \$93,035. During the same period, the Company saw net cash outflows of \$3,039 from operations and reported net current assets of \$23,643 as of December 31, 2025. In November 2025, the Company successfully secured additional debt financing for a five-year term.

The Company's ability to continue as a going concern is reliant on its ongoing ability to generate positive cash flows and achieve profitability.

***The Company's actual financial position and results of operations may differ materially from the expectations of the Company's management***

The Company's actual financial position and results of operations may differ materially from management's expectations. The Company has experienced some changes in its operating plans and certain delays in the timing of its plans. As a result, the Company's revenue, net income, and cash flow may differ materially from the Company's projected revenue, net income, and cash flow. The process for estimating the Company's revenue, net income and cash flow requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in planning may not prove to be accurate, and other factors may affect the Company's financial condition or results of operations.

***The Company may incur significant ongoing costs and obligations related to its investment in infrastructure, growth, regulatory compliance, and operations***

The Company may incur significant ongoing costs and obligations related to its investment in infrastructure and growth and for regulatory compliance, which could have a material adverse impact on the Company's results of operations, financial condition, and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company. The Company's efforts to grow its business may be more costly than expected, and the Company may not be able to increase its revenue enough to offset its higher operating expenses. The Company may incur significant losses in the future for a number of reasons, including unforeseen expenses, difficulties, complications and delays, and other unknown events. If the Company is unable to achieve and sustain profitability, the market price of the Common Shares may significantly decrease.

***There are factors which may prevent the Company from the realization of growth targets***

The Company is currently in the stage of expansion from early development. There is a risk that business objectives will not be achieved on time, on budget, or at all, as they can be adversely affected by a variety of factors, including some that are discussed elsewhere in these "Risk Factors" and the following:

- price compression
- reliance on the Pacifica Facility as the primary facility for its Canadian operations given the infancy of the Cascadia Facility;
- delays in obtaining, or conditions imposed by, regulatory approvals;
- facility design errors;
- the ability to launch new brands and products into new provinces and associated revenue;
- environmental pollution;
- non-performance by third party contractors;
- increases in materials or labour costs;
- construction performance falling below expected levels of output or efficiency;
- breakdown, aging or failure of equipment or processes;
- contractor or operator errors;
- operational inefficiencies;
- labour disputes, disruptions or declines in productivity;
- inability to attract sufficient numbers of qualified workers;
- disruption in the supply of energy and utilities;
- major incidents and/or catastrophic events such as fires, explosions, pandemics, or storms; and
- labour shortages and supply chain disruptions caused by global geopolitical events or pandemics.

***The Company may not be able to develop its products, which could prevent it from ever becoming profitable***

If the Company cannot successfully develop, manufacture, and distribute its products, or if the Company experiences difficulties in the development process, such as capacity constraints, quality control problems or other disruptions, the

Company may not be able to develop market-ready commercial products at acceptable costs, which would adversely affect the Company's ability to effectively enter the market. A failure by the Company to achieve a low-cost structure through economies of scale or improvements in cultivation and manufacturing processes would have a material adverse effect on the Company's commercialization plans and the Company's business, prospects, results of operations and financial condition.

***The Company may be unable to adequately protect its proprietary and intellectual property rights***

The Company's ability to compete may depend on the superiority, uniqueness, and value of any intellectual property and technology that it may develop. To the extent the Company is able to do so, to protect any proprietary rights of the Company, the Company intends to rely on a combination of patent, trademark, copyright and trade secret laws, confidentiality agreements with its employees and third parties, and protective contractual provisions. Despite these efforts, any of the following occurrences may reduce the value of any of the Company's intellectual property:

- the market for the Company's products and services may depend to a significant extent upon the goodwill associated with its trademarks and trade names;
- patents in the cannabis industry involve complex legal and scientific questions and patent protection may not be available for some or any products;
- the Company's applications for trademarks and copyrights relating to its business may not be granted and, if granted, may be challenged or invalidated;
- issued patents, trademarks and registered copyrights may not provide the Company with competitive advantages;
- the Company's efforts to protect its intellectual property rights may not be effective in preventing misappropriation of any of its products or intellectual property;
- the Company's efforts may not prevent the development and design by others of products similar to or competitive with, or superior to those the Company develops;
- another party may obtain a blocking patent and the Company would need to either obtain a license or design around the patent in order to continue to offer the contested feature or service in its products; or
- the expiration of patent or other intellectual property protections for any assets owned by the Company could result in significant competition, potentially at any time and without notice, resulting in a significant reduction in sales. The effect of the loss of these protections on the Company and its financial results will depend, among other things, upon the nature of the market and the position of the Company's products in the market from time to time, the growth of the market, the complexities, and economics of manufacturing a competitive product and regulatory approval requirements but the impact could be material and adverse.

***The Company may be forced to litigate to defend its intellectual property rights, or to defend against claims by third parties against the Company relating to intellectual property rights***

The Company may be forced to litigate to enforce or defend its intellectual property rights, to protect its trade secrets or to determine the validity and scope of other parties' proprietary rights. Any such litigation could be very costly and could distract its management from focusing on operating the Company's business. The existence and/or outcome of any such litigation could harm the Company's business. Further, because the content of much of the Company's intellectual property concerns cannabis and other activities that may not be legal in some foreign jurisdictions and the specifics of which may be unfamiliar to or misunderstood by courts, the Company may face additional difficulties in defending its intellectual property rights.

***The Company may become subject to litigation, including for possible product liability claims, which may have a material adverse effect on the Company's reputation, business, results from operations, and financial condition***

The Company may be named as a defendant in a lawsuit or regulatory action. The Company may also incur uninsured losses for liabilities which arise in the ordinary course of business, or which are unforeseen, including, but not limited to, employment liability and business loss claims. Any such losses could have a material adverse effect on the Company's business, results of operations, sales, cash flow or financial condition.

Further, the production of substances for use or consumption by humans can result in product liability claims by consumers. Product liability claims can be expensive, difficult to defend and may result in large judgments or settlements against the Company. The Company may not be able to obtain or maintain adequate insurance or other protection against potential liabilities arising from product sales. Product liability claims could also result in negative perception of the Company's products or other reputational damage which could have a material adverse effect on the Company's business, results of operations, sales, cash flow or financial condition.

***The Company faces competition from other companies where it will conduct business that have higher capitalization, and***

***may have more experienced management or be more mature as a business***

An increase in the companies competing in this industry could limit the ability of the Company to expand its operations. Current and new competitors may be better capitalized, have a longer operating history, have more expertise and may be able to develop higher quality equipment or products, at the same or a lower cost. The Company cannot provide assurances that it will be able to compete successfully against current and future competitors. Competitive pressures faced by the Company could have a material adverse effect on its business, operating results, and financial condition. In addition, despite Canadian federal legalization of marijuana, illicit or “black-market” operations remain abundant and present substantial competition to the Company. In particular, illicit operations, despite being largely clandestine, are not required to comply with the extensive regulations that the Company must comply with to conduct business, and accordingly may have significantly lower costs of operation.

***If the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis market***

The Company’s success has depended and continues to depend upon its ability to attract and retain key management, technical experts, and sales personnel. The Company will attempt to enhance its management and technical expertise by continuing to recruit qualified individuals who possess desired skills and experience in certain targeted areas. The Company’s inability to retain employees and attract and retain sufficient additional employees or engineering and technical support resources could have a material adverse effect on the Company’s business, results of operations, sales, cash flow or financial condition.

Shortages in qualified personnel or the loss of key personnel could adversely affect the financial condition of the Company, results of operations of the business and could limit the Company’s ability to develop and market its cannabis-related products. The loss of any of the Company’s senior management or key employees could materially adversely affect the Company’s ability to execute its business plan and strategy, and the Company may not be able to find adequate replacements on a timely basis, or at all. The Company does not maintain key person life insurance policies on any of our employees.

***The size of the Company’s target market is difficult to quantify and investors will be reliant on their own estimates on the accuracy of market data***

Because the cannabis industry is in a nascent stage with uncertain boundaries, there is a lack of information about comparable companies available for potential investors to review in deciding about whether to invest in the Company and, few, if any, established companies whose business model the Company can follow or upon whose success the Company can build. Accordingly, investors will have to rely on their own estimates in deciding about whether to invest in the Company. There can be no assurance that the Company’s estimates are accurate or that the market size is sufficiently large for its business to grow as projected, which may negatively impact its financial results.

***Risks Related to Third-Party Data***

The Company relies on independent third-party data for market share position and there is no assurance third party data provides an accurate representation of actual sales as some third parties use different methodologies or calculations to estimate market share position, and because market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. The Company also relies on its own market research and internal data to determine the accuracy of such third-party data.

***The Company may continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders***

The continued development of the Company will require additional financing. The failure to raise such capital could result in the delay or indefinite postponement of current business objectives or the Company going out of business. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favourable to the Company. If additional funds are raised through issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences, and privileges superior to those of holders of Common Shares. The Company’s articles permit the issuance of an unlimited number of Common Shares, and shareholders will have no pre-emptive rights in connection with such further issuance. The directors of the Company have discretion to determine the price and the terms of issue of further issuances. Moreover, additional Common Shares will be issued by the Company on the exercise of options under the Company’s stock

option plan and upon the exercise of outstanding warrants. In addition, from time to time, the Company may enter into transactions to acquire assets or the shares of other companies. These transactions may be financed wholly or partially with debt, which may temporarily increase the Company's debt levels above industry standards. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions. The Company may require additional financing to fund its operations to the point where it is generating positive cash flows. Negative cash flow may restrict the Company's ability to pursue its business objectives.

***The Company is exposed to credit risk on its cash and cash equivalents and accounts receivable***

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company is exposed to credit risk on its cash and cash equivalents and accounts receivable. The carrying amount of these assets represent the maximum credit exposure. The Company limits exposure to credit risk by maintaining its cash and cash equivalents and security deposits with institutions of high credit worthiness. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses credit quality of the counterparties, taking into account their financial position, past experience and other factors. Credit risk is mitigated by entering into arrangements with reputable and stable counterparties and frequent reviews of exposure to individual entities.

***The Company's operations are subject to risks and opportunities related to climate change***

These risks include, but are not limited to, chronic and acute physical risks such as the increasing frequency and severity of weather conditions. These events could damage or destroy the Company's operating facilities, adversely affect the Company's facility, or result in reduced transportation availability. These events could have a similar effect on the facilities of the Company's suppliers and customers. Any of the damage caused by these events could increase costs and decrease production capacity at the Company's operations having an adverse effect on the Company's financial results. The Company believes there are reasonable internal processes and insurance arrangements in place to mitigate or cover certain outcomes of such incidents; however, there is no guarantee that these arrangements will fully protect the Company against such losses.

There are also transition risks associated with climate change. These include changes in laws, regulations and industry standards associated with greenhouse gas emissions management, as well as non-regulatory pressure to reduce greenhouse gas emissions, and changing consumer preferences for sustainable products. The Company monitors regulatory changes including any climate-related regulations, to assess their impacts on operations. The Company publishes an annual Environment, Social, and Governance ("ESG") report and is committed to integrating ESG considerations into its operations.

***Environmental and employee health and safety regulations***

The Company's operations are subject to environmental and safety laws and regulations concerning, among other things, emissions and discharges to water, air and land, the handling and disposal of hazardous and non-hazardous materials and wastes, and employee health and safety. The Company will incur ongoing costs and obligations related to compliance with environmental and employee health and safety matters. Failure to comply with environmental and safety laws and regulations may result in additional costs for corrective measures, penalties or in restrictions on our manufacturing operations. In addition, changes in environmental, employee health and safety or other laws, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

***The Company may face restrictions or limitations in accessing banking and financial services due to the nature of its operations in the cannabis industry***

The Company is subject to risks associated with accessing and maintaining banking and financial services in Canada. Despite the legalization of cannabis, financial institutions may classify cannabis-related businesses as high-risk clients under the Canadian anti-money laundering regime, which can result in increased scrutiny, additional compliance requirements, or the potential restriction of banking services. The obligation imposed on financial institutions to conduct ongoing monitoring of cannabis-related clients and their activities may result in increased costs, administrative burden, or disruption to the Company's banking relationships. Any loss of, or inability to maintain, adequate banking and financial services could have a material adverse effect on the Company's operations and financial position.

***The Company currently has insurance coverage; however, because the Company operates within the cannabis industry, there are additional difficulties, complexities, and costs associated with such insurance coverage***

The Company believes that it and its subsidiaries currently have insurance coverage with respect to workers' compensation, general liability, directors' and officers' insurance, fire and other similar policies customarily obtained for businesses to the extent commercially appropriate; however, because the Company is engaged in and operates within the cannabis industry, there are exclusions and additional difficulties and complexities associated with such insurance coverage that could cause the Company to suffer uninsured losses, which could adversely affect the Company's business, results of operations, and profitability. There is no assurance that the Company will be able to obtain insurance coverage at a reasonable cost or fully utilize such insurance coverage, if necessary. Additionally, the Company may experience losses that our insurance policies have specific exclusions for or events that the Company is unable obtain insurance at reasonable pricing, such as flood insurance for the Pacifica Facility, for resulting in losses having material adverse effects.

***Obtaining new strains and developing new product offerings may not be successful or aligned to consumer demands***

While the Company has proven to be successful at acquiring and growing new strains, there is no guarantee the Company will continue to be able to acquire and cultivate new strains in the future. The prevailing challenges in obtaining new strains are compounded by the intricate legal processes involved. These regulatory constraints not only present hurdles for legitimate enterprises like ours but also inadvertently confer a competitive advantage to the illicit market, which operates outside the bounds of such restrictions. Furthermore, there is no certainty that the selected strains and new products offerings will have sufficient consumer demand to be sold for a profit, if at all. An inability to access new strains or innovate new products, which delight consumers may results in depressed sales, product returns, inventory write-offs, and other adverse impacts on the Company's operations.

***The cultivation of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others***

The Company's future business involves the growing of cannabis, an agricultural product. Such business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although the Company expects that any such growing will be completed indoors under climate-controlled conditions, there can be no assurance that natural elements will not have a material adverse effect on any such future production. There is also no guarantee that natural elements will not impact the health, yield, consistency, or consumer appeal of product.

***The cultivation of cannabis involves a reliance on third party transportation which could result in supply delays, reliability of delivery and other related risks***

In order for customers of the Company to receive their product, the Company relies on third party transportation services. This can cause logistical problems and delays in customers obtaining their orders and cannot be directly controlled by the Company. Any delay by third party transportation services may adversely affect the Company's reputation and financial performance.

Moreover, security of the product during transportation to and from the Company's facilities is critical due to the nature of the product. A breach of security during transport could have material adverse effects on the Company's business, financials, and prospects. Any such breach could impact the Company's future ability to continue operating under its licenses or the prospect of renewing its licenses.

***The Company may be subject to product recalls for product defects self-imposed or imposed by regulators***

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of the Company's products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may lose a significant number of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency, or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action, or lawsuits. Additionally, if one of the Company's significant brands were subject to recall, the image of that brand and the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company's products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to increased scrutiny of the Company's operations by

Health Canada or other regulatory agencies, requiring further management attention and potential legal fees and other expenses.

***The Company is reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on the Company's finances and operational results***

The Company's business is dependent on a number of key inputs and their related costs including raw materials and supplies related to its growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition, and operating results of the Company. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition, and operating results of the Company.

***The Company could be liable for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses to claims against the Company***

The Company is exposed to the risk that its employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to the Company that violates: (i) government regulations; (ii) manufacturing standards; (iii) federal and provincial healthcare fraud and abuse laws and regulations; or (iv) laws that require the true, complete, and accurate reporting of financial information or data. It is not always possible for the Company to identify and deter misconduct by its employees and other third parties, and the precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against the Company, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on the business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the Company's operations, any of which could have a material adverse effect on the Company's business, financial condition and results of operations.

***Advent of Technology driven by Artificial Intelligence ("AI")***

With new technologies and systems developed that leverage artificial intelligence, this could result in the Company's competitors gaining an advantage. Examples include AI-driven cultivation optimization that could lead to yield improvements, or improved demand forecasting and pricing optimization that is backed with insights obtained through AI. This could reduce the Company's market share if such competitors are able to leverage these tools and be more competitive.

***The Company will be reliant on information technology systems and may be subject to damaging cyber-attacks***

The Company has entered into agreements with third parties for hardware, software, telecommunications, and other information technology ("IT") services in connection with its operations. The Company's operations depend, in part, on how well it and its suppliers protect networks, equipment, IT systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, pandemics, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. The Company's operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact the Company's reputation and results of operations.

The Company has not experienced any material losses to date relating to cyber-attacks or other information security breaches, but there can be no assurance that the Company will not incur such losses in the future. The Company's risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access is a priority. As cyber threats continue to evolve, the Company may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

***The Company may be subject to breaches of security at its facilities, or in respect of electronic documents and data storage***

***and may face risks related to breaches of applicable privacy laws***

Given the nature of the Company's product and its lack of legal availability outside of appropriately licensed channels, as well as the concentration of inventory in its facilities, despite meeting or exceeding Health Canada's security requirements, there remains a risk of shrinkage as well as theft. A security breach at one of the Company's facilities could expose the Company to additional liability and to potentially costly litigation, increase expenses relating to the resolution and future prevention of these breaches and may deter potential patients from choosing the Company's products.

***The Company's officers and directors may be engaged in a range of business activities resulting in conflicts of interest***

The Company may be subject to various potential conflicts of interest because some of its officers and directors may be engaged in a range of business activities. In addition, the Company's executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to the Company. In some cases, the Company's executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to the Company's business and affairs and that could adversely affect the Company's operations. These business interests could require significant time and attention of the Company's executive officers and directors.

In addition, the Company may also become involved in other transactions which conflict with the interests of its directors and the officers who may from time-to-time deal with persons, firms, institutions or companies with which the Company may be dealing, or which may be seeking investments similar to those desired by it. The interests of these persons could conflict with those of the Company. In addition, from time to time, these persons may be competing with the Company for available investment opportunities. Conflicts of interest, if any, will be subject to the procedures and remedies provided under applicable laws. In particular, if such a conflict of interest arises at a meeting of the Company's directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms. In accordance with applicable laws, the directors of the Company are required to act honestly, in good faith and in the best interests of the Company.

***The Company may expand our business and operations into jurisdictions outside of Canada, and there are risks associated with doing so***

The Company may expand our operations and business into jurisdictions outside of Canada, but there can be no assurance that any market for our products will develop in any such foreign jurisdiction. The expansion of our operations internationally will depend on our ability to renew or secure the necessary permits, licenses, or other approvals in those jurisdictions. An agency's denial of or delay in issuing or renewing a permit, license, or other approval, or revocation or substantial modification of an existing permit or approval, could prevent us from continuing our operations in or exports to other countries.

Operations in non-Canadian markets may expose us to new or unexpected risks or significantly increase our exposure to one or more existing risk factors. In addition, Rubicon is subject to a wide variety of laws and regulations domestically and internationally with respect to the flow of funds and product across international borders and the amount of medical cannabis the Company exports may be limited by the various drug control conventions to which Canada is a signatory.

While Rubicon continues to monitor developments and policies in the emerging markets in which the Company operates and assess the impact thereof to our operations, such developments cannot be accurately predicted and could have an adverse effect on the Corporation's business, operations, or profitability.

***In certain circumstances, the Company's reputation could be damaged***

Damage to the Company's reputation can be the result of the actual or perceived occurrence of any number of events, and could include any negative publicity, whether true or not. The increased usage of social media and other web-based tools used to generate, publish, and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share opinions and views regarding the Company and its activities, whether true or not. Although the Company believes that it operates in a manner that is respectful to all stakeholders and that it takes care in protecting its image and reputation, the Company does not ultimately have direct control over how it is perceived by others. Reputation loss may result in decreased investor confidence, increased challenges in developing and maintaining community relations and an impediment to the Company's overall ability to advance its projects, thereby having a material adverse impact on financial performance, financial condition, cash flows and growth prospects.

***The Company targets, among other segments, the premium adult-use cannabis market, which may not materialize, or in which the Company may not be able to develop or maintain a brand that attracts or retains customers***

The Company targets users of cannabis in the Canadian adult-use cannabis market who are looking for premium products; however, such a market may not materialize or be sustainable. If this premium market does materialize, the Company may not be successful in creating and maintaining consumer perceptions of the value of premium products. The promotion of cannabis is strictly regulated in Canada. For example, promotion is largely restricted to the place of sale and subject to prescribed conditions set out in the Cannabis Act, the Cannabis Regulations and Further Regulations. Among other restrictions, the Cannabis Act prohibits testimonials and endorsements, lifestyle branding and promotion that is appealing to young persons. Such restrictions on advertising, marketing and the use of logos and brand names, and other restrictions on advertising imposed by Canadian federal or provincial laws or regulations, or similar regulations imposed in other jurisdictions, may prevent the Company from creating and maintaining consumer perceptions in the value of its premium products and establishing itself as a premium producer. If the Company cannot successfully compete in the premium market, the Company may face significant challenges in gaining or maintaining a market share in Canada or in other cannabis markets in which it operates, or it may be forced to sell products at a lower price, which may materially adversely affect results of operations.

***The Company may not be able to maintain its TSX-V listing requirements***

The Company must maintain the listing requirements of the TSX-V to continue being listed. The inability to meet or maintain these listing requirements could adversely affect the results of the Company's operations or its financial condition.

***Necessary security clearances take time to obtain and may impact the Company's ability to attract and retain board members and officers***

The Cannabis Act and Cannabis Regulations require several individuals to obtain and maintain a valid security clearance, including directors, officers, and large shareholders of the Company. A security clearance cannot be valid for more than five years and must be renewed before the expiry of a current security clearance. There is no assurance that any of the Company's existing directors and officers who presently or may in the future require a security clearance will be able to obtain or renew such clearances or that new personnel who require a security clearance will be able to obtain one. Prospective qualified directors or officers may be deterred from accepting appointments to positions in the cannabis industry that require security clearances due to the onus of the lengthy application process and uncertainty that a security clearance will be granted at all. Inability to attract and retain such qualified directors and officers may result in a material adverse effect on the Company's business, operating results, financial condition, or prospects.

***There is no certainty the Company will be able to achieve its Environmental, Social and Governance ("ESG") targets***

While the Company has incorporated certain ESG objectives into its strategic plan it may not be economically feasible to execute the desired changes to the business. The Company's inability to achieve its ESG objects may have effects on its social license to operate, brand equity, and corporate identity, which could have knock on impacts to operations, hiring, and the sale of product.

***The cost of compliance and ability to working with unsophisticated individuals and entities may adversely impact the Company***

The market for cannabis products is highly volatile. Many entities and persons operating in the industry were formerly involved in the illegal market. Some still are, and many operate in unconventional ways. Some of these unconventional ways, which represent challenges to the Company, include not keeping appropriate financial records, inexperience with business contracts, not having access to customary business banking relationships, not having quality manufacturing relationships, and not having customary distribution arrangements. They may not be accustomed to entering into written agreements or keeping financial records according to Generally Accepted Accounting Principles. These entities and persons may not pay attention to obligations to which they have agreed in written contracts. Therefore, it may become challenging for the Company to enter into more complex commercial transactions, which could limit the Company's growth or otherwise adversely affect the Company. Any one of these challenges, if not managed, could adversely impact the Company. These challenges may also increase the cost of the Company's operations in the near-term.

***The Company has a limited operating history, a history of losses and the Company cannot assure profitability***

Up until Q2 2022, the Company had been incurring operating losses and cash flow deficits since the inception of such operations, as it attempted to create an infrastructure to capitalize on the opportunity for value creation that is emerging from the legalization of recreational cannabis in Canada. The Company's lack of operating history makes it difficult for investors to evaluate the Company's prospects for success. Prospective investors should consider the risks and difficulties the Company might encounter, especially given the Company's lack of an operating history, there is no assurance that the Company will be successful, and the likelihood of success must be considered in light of its relatively early stage of operations.

### ***Organic Certification and Products***

The Company believes that organic products will command a higher price in the marketplace and has completed an organic certification process with FVOPA, a leading organization in organic certification in Canada. FVOPA provides inspection and certification for sustainable development and maintains organic standards on products, systems, and services. The certification process generally includes validation of inputs, production methods and preparation procedures in accordance with Canadian organic product regulation. Organic certification aims to guarantee the organic integrity of products throughout the entire production chain. Failure to maintain the organic standards may have an adverse effect on the market price of the Company's products.

### ***Reliance on Licenses***

The viability of Rubicon Organics' business of growing, storing, and distributing medical and recreational cannabis is dependent on the good standing of all licenses required to engage in such activities and upon adhering to all regulatory requirements related to such activities. The two main category of licenses that the company relies upon are the Health Canada licenses and the Canada Revenue Agency ("CRA") Excise license. Effective October 17, 2025, the Company renewed its Health Canada licenses for the Pacifica facility. The Health Canada licenses are valid until October 17, 2030, at which point, RHC must apply to Health Canada for renewal. Effective September 1, 2024 the Company renewed its CRA license. The CRA license is valid until January 26, 2027. The CRA license was amended on November 10, 2025 to include the addition of the Cascadia Facility.

Failure to comply with the requirements of the licenses or any failure to maintain the licenses would have a material adverse impact on the business, financial condition, and operating results of Rubicon Organics. Although Rubicon Organics believes it will meet the requirements of the Cannabis Act and the Excise Act for future extensions or renewal of the licenses, there can be no guarantee that Health Canada or the CRA will extend or renew the licenses or that, if extended or renewed, the licenses will be extended or renewed on the same or similar terms. Should Health Canada or the CRA not extend or renew the licenses, or should it renew the licenses on different terms, the business, financial condition, and results of operations of Rubicon Organics could be materially and adversely affected.

### ***Supplier Risk and Industry Disruptions***

The Company is dependent on a variety of suppliers for critical materials, equipment, and services necessary to operate its facilities and meet production goals. The ability of these suppliers to fulfill their obligations may be impacted by factors outside the Company's control, including disruptions in their operations, financial difficulties, or insolvency proceedings such as those under the Companies' Creditors Arrangement Act ("CCAA"). Should key suppliers experience operational failures, supply chain issues, or financial instability, it could result in delays, increased costs, or interruptions to the Company's production timelines. These disruptions could hinder the Company's ability to maintain consistent product supply, meet market demand, and achieve revenue targets.

As the cannabis industry is subject to specific regulatory requirements, any supplier non-compliance with applicable regulations could further complicate the Company's ability to operate and could expose the Company to legal and financial risks. The Company is proactively managing its supplier relationships, however, there is no assurance that the Company will be able to fully mitigate these risks, and any supplier failure could have a material adverse effect on the Company's operations, financial results, and ability to satisfy customer demand.

***Failure to develop and maintain an effective system of internal controls increases the risk that the Company may not be able to accurately and reliably report our financial results or prevent fraud, which may harm our business, the trading price of our Common Shares and market value of other securities***

The Company maintains a system of internal controls over financial reporting ("ICFR") to ensure the Company's financial

reporting is reliable and that its financial statements have been prepared in accordance with IFRS. Regardless of how well controls are designed, internal controls have inherent limitations and can only provide reasonable assurance that the controls are meeting the Company's objectives in providing reliable financial reporting information in accordance with IFRS. Effective internal controls are required for us to provide reasonable assurance that our financial results and other financial information are accurate and reliable. Any failure to design, develop or maintain effective controls, or difficulties encountered in implementing, improving or remediation lapses in internal controls may affect our ability to prevent fraud, detect material misstatements, and fulfill our reporting obligations. As a result, investors may lose confidence in our ability to report timely, accurate and reliable financial and other information, which may expose us to certain legal or regulatory actions, thus negatively impacting our business, the trading process of our Common Shares and market value of other securities.

***Participants in the cannabis industry may have difficulty accessing the service of banks and financial institutions, which may make it difficult for us to operate***

Because cannabis remains illegal federally in the United States, Canadian banks and financial institutions with U.S. affiliations remain wary of providing services to businesses in the cannabis industry, as the associated funds may technically be considered proceeds of crime in the U.S. Consequently, businesses involved in the cannabis industry continue to have trouble establishing banking infrastructure and relationships. The inability or limitation on our ability to open or maintain a bank account, obtain other banking services, or obtain business services may make it difficult to operate and conduct business.

***Reliance on business partners to supply products to the Company's quality standards***

The Company has entered into, and will enter, third-party agreements to launch new innovation and supply our customers given capacity constraints and to produce products not capable of being produce from the Pacifica Facility. Despite rigorous due-diligence, there are inherent risks including quality control risk issues, and delay in responding to quality issues, where the third-party supplier may not consistently meet the quality standards expected by the Company resulting in defective products being delivered to the customers, leading to dissatisfaction and potential damage to the Company's reputation. Also dependency risk: Depending heavily on third-party suppliers can create a dependency risk. If a supplier encounters difficulties or goes out of business, it could disrupt the supply chain and impact the business's operations. Finally, compliance and regulatory risks: If the third-party supplier fails to comply with relevant regulations or standards, it could result in legal and regulatory consequences for the business. This includes issues related to product safety and environmental regulations.

The Company has engaged in, and will continue to pursue, strategic partnerships with third-party entities to drive innovation and fulfill customer demand, particularly in light of capacity limitations and the need to manufacture products beyond the capabilities of the Pacifica Facility. Despite thorough due diligence, there are inherent risks. These encompass potential challenges in maintaining quality control standards, as well as delays in addressing quality issues, wherein third-party suppliers may not consistently align with the Company's stringent quality expectations. Such discrepancies could lead to the delivery of defective products, resulting in customer dissatisfaction and possible harm to the Company's reputation.

Furthermore, heavy reliance on third-party suppliers introduces dependency risks. Should a supplier encounter difficulties or cease operations, it could disrupt the supply chain, impacting the Company's operational continuity. Additionally, compliance and regulatory risks due to failure on the part of third-party suppliers to adhere to pertinent regulations or standards may expose the Company to legal and regulatory ramifications, particularly concerning product safety and environmental compliance.

***Valuation of cannabis plants***

Pursuant to IFRS, the Company measures the value of its cannabis plants using the income approach at fair value less costs to sell up to the point of harvest. As market prices are generally not available for cannabis plants while they are growing, the Company is required to make assumptions and estimates relating to, among other things, future plant yields, cannabis prices and production costs. The assumptions and estimates used to determine the fair value of the cannabis plants, and any changes to such prior estimates, directly affect the Company's reported results of operations. If actual yields, prices, costs, market conditions or other results differ from the Company's estimates and assumptions, there could be material adjustments to the Company's results of operations.

***Transition to Enterprise Resource Planning ("ERP") system***

The Company began implementing an ERP system in January 2024, marking the start of a multi-year transition from its previous stand-alone systems. This strategic initiative is expected to drive long-term efficiencies and is viewed as a critical

step toward supporting future growth by establishing a unified operational platform. However, this transition has led to short-term, non-recurring costs, the majority of which were incurred in 2024, as well as associated risks, though these costs and risks have carried over into 2025. These risks include the possibility of exceeding the budget for implementation, which covers software, hardware, infrastructure, training, and consultancy fees. Additionally, a temporary dip in productivity is anticipated as staff undergo training to develop the necessary skills to effectively use the new system. Though the Company has completed the data migration process from existing systems to the new ERP platform, risks in the form of undetected errors during the transition process remain.

### ***Risks regarding vaping products***

Between 2021 and 2022, the Company sold Simply Bare™ Organic branded PAX® pods for distribution in Canada. In 2024, the Company began selling 1964 Supply Co™ 510-thread vapes for distribution in Canada. In 2025, the Company launched All-In-One (“AIO”) Full Spectrum Extract (“FSE”) Resin Vapes under the 1964 Supply Co™ brand. The Company may also launch other vaping related products in the future. In Canada there have been public warnings to stop using certain vaping liquids containing cannabis derivatives and ingredients, such as CBD and THC, in light of a potential but unconfirmed link to lung injuries such as severe pulmonary illness. Reported lung injuries associated with the use of cannabis derivative containing vaping liquids have resulting in certain provinces either banning or delaying the sale of vaping liquids and vaping products to consumers. In response, Health Canada issued an information update advising Canadians who use cannabis derivative containing vaping liquids to monitor themselves for symptoms of pulmonary illness. There may be further governmental and private sector actions aimed at reducing the sale of or prohibiting cannabis containing vaping liquids and/or seeking to hold manufacturers of cannabis containing vaping liquids responsible for the adverse health effects associated with the use of these vaping products. These actions, combined with potential deterioration in the public’s perception of cannabis containing vaping liquids, may result in a reduced market for the Company’s vaporizer products. Federal, provincial, and local regulations or actions that prohibit or restrict the sale of the Company’s vaporizer products including cannabis derivative vaping liquids, or that decrease consumer demand for the Company’s products by prohibiting their use, raising the minimum age for their purchase, raising the purchase prices to unattractive levels via taxation, or banning their sale, could adversely impact the Company’s business, financial condition, results of operations and prospects.

### ***Facility Optimization and Expansion***

The optimization of the Pacifica and Cascadia Facilities are subject to various potential problems and uncertainties and such optimization may be delayed or adversely affected by a number of factors beyond Rubicon Organics’ control. These uncertainties include the failure to obtain regulatory approvals, permits, delays in the delivery or installation of equipment by suppliers, difficulties in integrating new equipment with existing facilities, shortages in materials or labor, defects in design, diversion of management resources, and insufficient funding or other resource constraints. The actual cost of the optimization may exceed the amount budgeted. As the result of delays, cost overruns, changes in market circumstances or other factors, Rubicon Organics may not be able to achieve the intended economic benefits from the optimization of the Pacifica Facility, which in turn may affect Rubicon Organics’ business, prospects, financial condition, and results of operations. Any future expansion of the Pacifica Facility is subject to Health Canada regulatory approvals. The delay or denial of such approvals may have a material adverse impact on the business of Rubicon Organics and may result in Rubicon Organics not meeting anticipated or future demand when it arises.

### ***Acquisition and Integration of the Cascadia Facility***

The Company acquired the Cascadia Facility, a purpose-built indoor cultivation facility located in Hope, British Columbia on June 5, 2025. As the Company integrates the Cascadia Facility into its existing operations, this process will present challenges, including the need to align operational processes, systems, and staffing. Any disruptions or inefficiencies during the integration could hinder production and delay the anticipated increase in production capacity. The Cascadia Facility is expected to increase the Company’s production capacity, with an estimated annual output of up to 4,500 kgs. However, achieving these production targets will depend on various factors, including the performance of cultivation systems, staffing, and the reliability of the supply chain. Any operational issues or unexpected obstacles could limit the Company’s ability to meet production goals, which may, in turn, affect its ability to fulfill market demand.

Although the Company has an experienced team, there is no guarantee of successful economic harvests from the new facility, and there are risks of going over budget. Any operational issues or unexpected obstacles could limit the Company’s ability to meet production goals, which may, in turn, affect its ability to fulfill market demand.

While the Company has received its license to cultivate, process, and store cannabis from Health Canada on October 20,

2025 and expects its first harvest from the Cascadia Facility in 2026, any future delays in regulatory approvals or operational readiness could impact production timelines, potentially impacting the Company's ability to meet market demand and achieve the expected revenue from the new facility.

## **Risks Related to the Company's Securities**

### ***The Company's securities have not been registered under the U.S. Securities Act***

The Common Shares have not been, and may never be, registered under the U.S. Securities Act or under applicable state or foreign securities laws. In addition, subscribers may be unable to deposit Rubicon Organics securities with a U.S. brokerage house.

### ***The market price for Common Shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond the Company's control***

The market price for Common Shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond the Company's control, including the following:

- actual or anticipated fluctuations in the Company's quarterly results of operations;
- recommendations by securities research analysts;
- changes in the economic performance or market valuations of companies in the industry in which the Company operates;
- addition or departure of the Company's executive officers and other key personnel;
- release or expiration of lock-up or other transfer restrictions on outstanding Common Shares;
- sales or perceived sales of additional Common Shares;
- significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by, or involving, U.S. entities or the Company's competitors;
- fluctuations to the costs of vital production materials and services;
- changes in global financial markets and global economies and general market conditions, such as interest rates and pharmaceutical product price volatility;
- operating and share price performance of other companies that investors deem comparable to the Company or from a lack of market comparable companies;
- impacts from pandemics or other major global events;
- news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in the Company's industry or target markets; and
- regulatory changes in the industry.

Financial markets have recently experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of companies, in particular Canadian cannabis companies, and that have often been unrelated to the operating performance, underlying asset values or prospects of such companies. Accordingly, the market price of the Common Shares may decline even if the Company's operating results, underlying asset values or prospects have not changed. Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which might result in impairment losses. There can be no assurance that continuing fluctuations in price and volume will not occur. If such increased levels of volatility and market turmoil continue, the Company's operations could be adversely affected and the trading price of the Common Shares might be materially adversely affected.

### ***The Company does not anticipate paying dividends***

The Company's current policy is to retain earnings to finance the development and enhancement of the Company's products and to otherwise reinvest in the Company. Therefore, the Company does not anticipate paying dividends on the Common Shares in the foreseeable future. The Company's dividend policy will be reviewed from time to time by the Board in the context of the Company's earnings, financial condition, and other relevant factors. Until the time that the Company does pay dividends, which the Company may never do, the Company's shareholders will not be able to receive a return on their Common Shares unless they sell them.

### ***Dilution to Common Shares***

The increase in the number of Common Shares issued and outstanding as a result of public offerings, may have a depressive

effect on the price of the Common Shares. In addition, as a result of such additional Common Shares, the ownership of the business and voting power of the Company's existing shareholders will be diluted.

***Loss on Dissolution or Termination of the Company***

Upon the dissolution and termination of the Company, the proceeds realized from the liquidation of assets, if any, will be distributed to the shareholders only after the claims of all creditors have been satisfied. Accordingly, the ability of a shareholder to recover all or any portion of its investment under such circumstances will depend on the amount of funds so realized and the claims to be satisfied from such funds.

***Concentrated Ownership of the Company***

At the date of this document, Insiders and Management collectively hold 43% of the Company's issued and outstanding Common Shares resulting in a concentrated ownership structure. Such concentrated ownership may present challenges for shareholders due to potential impacts on stock liquidity and market dynamics. Consequently, shareholders might encounter difficulties in buying or selling shares without experiencing considerable price fluctuations or delays.

**ADDITIONAL INFORMATION**

Additional financial information is also provided in the Company's audited financial statements and related management's discussion and analysis for the fiscal year ended December 31, 2025.

Additional information, including directors' and officers' remuneration and indebtedness, principal holders of the Company's securities, and securities authorized for issuance under equity compensation plans, is contained in the Company's management information circular for the most recent annual meeting of shareholders. Additional information relating to Rubicon Organics can be found on the SEDAR+ website at [www.sedarplus.ca](http://www.sedarplus.ca).